tooluniverse-drug-research

Compare original and translation side by side

🇺🇸

Original

English
🇨🇳

Translation

Chinese

Drug Research Strategy

药物研究策略

Comprehensive drug investigation using 50+ ToolUniverse tools across chemical databases, clinical trials, adverse events, pharmacogenomics, and literature.
KEY PRINCIPLES:
  1. Report-first approach - Create report file FIRST, then populate progressively
  2. Compound disambiguation FIRST - Resolve identifiers before research
  3. Citation requirements - Every fact must have inline source attribution
  4. Evidence grading - Grade claims by evidence strength
  5. Mandatory completeness - All sections must exist, even if "data unavailable"
  6. English-first queries - Always use English drug/compound names in tool calls, even if the user writes in another language. Only try original-language terms as a fallback. Respond in the user's language

利用50+ ToolUniverse工具,跨化学数据库、临床试验、不良事件、药物基因组学和文献资源开展全面药物调研。
核心原则:
  1. 报告优先方法 - 先创建报告文件,再逐步填充内容
  2. 化合物消歧优先 - 先解析化合物标识符再开展研究
  3. 引用要求 - 所有事实必须附带内联来源归因
  4. 证据分级 - 根据证据强度对研究结论分级
  5. 强制完整性 - 所有章节必须存在,即使标注“数据不可用”
  6. 英文优先查询 - 工具调用中始终使用英文药物/化合物名称,即使用户使用其他语言提问。仅在回退时尝试原语言术语。用用户的语言回复

Critical Workflow Requirements

关键工作流要求

1. Report-First Approach (MANDATORY)

1. 报告优先方法(强制要求)

DO NOT show the search process or tool outputs to the user. Instead:
  1. Create the report file FIRST - Before any data collection, create a markdown file:
    • File name:
      [DRUG]_drug_report.md
      (e.g.,
      metformin_drug_report.md
      )
    • Initialize with all 11 section headers from the template
    • Add placeholder text:
      [Researching...]
      in each section
  2. Progressively update the report - As you gather data:
    • Update each section with findings immediately after retrieving data
    • Replace
      [Researching...]
      with actual content
    • The user sees the report growing, not the search process
  3. Use ALL relevant tools - For comprehensive coverage:
    • Query multiple databases for each data type
    • Cross-reference information across sources
    • Use fallback tools when primary tools return limited data
禁止向用户展示搜索过程或工具输出。需遵循以下步骤:
  1. 先创建报告文件 - 在收集任何数据前,创建一个Markdown文件:
    • 文件名:
      [DRUG]_drug_report.md
      (例如:
      metformin_drug_report.md
    • 从模板初始化所有11个章节标题
    • 在每个章节添加占位文本:
      [调研中...]
  2. 逐步更新报告 - 收集数据后:
    • 获取数据后立即更新对应章节
    • 用实际内容替换
      [调研中...]
    • 用户仅能看到报告内容的逐步完善,而非搜索过程
  3. 使用所有相关工具 - 确保覆盖全面:
    • 针对每种数据类型查询多个数据库
    • 跨来源交叉验证信息
    • 当主工具返回数据有限时,使用备用工具

2. Citation Requirements (MANDATORY)

2. 引用要求(强制要求)

Every piece of information MUST include its source. Use inline citations:
markdown
undefined
每条信息必须包含来源。使用内联引用格式:
markdown
undefined

3. Mechanism & Targets

3. 作用机制与靶点

3.1 Primary Mechanism

3.1 主要作用机制

Metformin activates AMP-activated protein kinase (AMPK), reducing hepatic glucose production and increasing insulin sensitivity in peripheral tissues.
Source: PubChem via
PubChem_get_drug_label_info_by_CID
(CID: 4091)
二甲双胍激活AMP激活的蛋白激酶(AMPK),减少肝脏葡萄糖生成并提高外周组织的胰岛素敏感性。
来源:PubChem via
PubChem_get_drug_label_info_by_CID
(CID: 4091)

3.2 Primary Target(s)

3.2 主要靶点

TargetUniProtActivityPotencySource
AMPK (PRKAA1)Q13131ActivatorEC50 ~10 µMChEMBL
Mitochondrial Complex I-InhibitorIC50 ~1 mMLiterature
Source: ChEMBL via
ChEMBL_get_target_by_chemblid
(CHEMBL1431)
undefined
靶点UniProt活性类型效价来源
AMPK (PRKAA1)Q13131激活剂EC50 ~10 µMChEMBL
线粒体复合物I-抑制剂IC50 ~1 mM文献
来源:ChEMBL via
ChEMBL_get_target_by_chemblid
(CHEMBL1431)
undefined

Citation Format

引用格式

For each data section, include at the end:
markdown
---
**Data Sources for this section:**
- PubChem: `PubChem_get_compound_properties_by_CID` (CID: 4091)
- ChEMBL: `ChEMBL_get_bioactivity_by_chemblid` (CHEMBL1431)
- DGIdb: `DGIdb_get_drug_info` (metformin)
---
在每个数据章节末尾添加:
markdown
---
**本节数据来源**:
- PubChem: `PubChem_get_compound_properties_by_CID` (CID: 4091)
- ChEMBL: `ChEMBL_get_bioactivity_by_chemblid` (CHEMBL1431)
- DGIdb: `DGIdb_get_drug_info` (metformin)
---

3. Progressive Writing Workflow

3. 渐进式写作工作流

Step 1: Create report file with all section headers
Step 2: Resolve compound identifiers → Update Section 1
Step 3: Query PubChem/ADMET-AI/DailyMed SPL → Update Section 2 (Chemistry)
Step 4: Query FDA Label MOA + ChEMBL activities + DGIdb → Update Section 3 (Mechanism & Targets)
Step 5: Query ADMET-AI tools → Update Section 4 (ADMET)
Step 6: Query ClinicalTrials.gov → Update Section 5 (Clinical Development)
Step 7: Query FAERS/DailyMed → Update Section 6 (Safety)
Step 8: Query PharmGKB → Update Section 7 (Pharmacogenomics)
Step 9: Query DailyMed → Update Section 8 (Regulatory)
Step 10: Query PubMed/literature → Update Section 9 (Literature)
Step 11: Synthesize findings → Update Executive Summary & Section 10
Step 12: Document all sources → Update Section 11 (Data Sources)
步骤1:创建包含所有章节标题的报告文件
步骤2:解析化合物标识符 → 更新第1节
步骤3:查询PubChem/ADMET-AI/DailyMed SPL → 更新第2节(化学特性)
步骤4:查询FDA标签作用机制 + ChEMBL活性数据 + DGIdb → 更新第3节(作用机制与靶点)
步骤5:查询ADMET-AI工具 → 更新第4节(ADMET特性)
步骤6:查询ClinicalTrials.gov → 更新第5节(临床开发)
步骤7:查询FAERS/DailyMed → 更新第6节(安全性)
步骤8:查询PharmGKB → 更新第7节(药物基因组学)
步骤9:查询DailyMed → 更新第8节(监管信息)
步骤10:查询PubMed/文献 → 更新第9节(文献研究现状)
步骤11:综合研究结果 → 更新执行摘要与第10节
步骤12:记录所有来源 → 更新第11节(数据来源与方法学)

4. Report Detail Requirements

4. 报告细节要求

Each section must be comprehensive and detailed:
  • Tables: Use tables for structured data (targets, trials, adverse events)
  • Lists: Use bullet points for features, findings, key points
  • Paragraphs: Include narrative summaries that synthesize findings
  • Numbers: Include specific values, counts, percentages (not vague terms)
  • Context: Explain what the data means, not just what it is
BAD (too brief):
markdown
undefined
每个章节必须全面且详细:
  • 表格: 结构化数据(靶点、试验、不良事件)使用表格呈现
  • 列表: 特性、研究结果、关键点使用项目符号
  • 段落: 包含综合研究结果的叙述性摘要
  • 数值: 包含具体数值、计数、百分比(避免模糊表述)
  • 背景: 解释数据的意义,而非仅罗列数据
错误示例(过于简略):
markdown
undefined

Clinical Trials

临床试验

Multiple trials completed. Approved for diabetes.

**GOOD** (detailed with sources):
```markdown
多项试验已完成。获批用于糖尿病。

**正确示例**(带来源的详细内容):
```markdown

5.2 Clinical Trial Landscape

5.2 临床试验现状

PhaseTotalCompletedRecruitingStatus
Phase 4897212Post-marketing
Phase 315613415Pivotal
Phase 220317818Dose-finding
Phase 167614Safety
Source: ClinicalTrials.gov via
search_clinical_trials
(intervention="metformin")
Total Registered Trials: 515 (as of 2026-02-04) Primary Indications Under Investigation: Type 2 diabetes (312), PCOS (87), Cancer (45), Obesity (38), NAFLD (33)
试验阶段总数已完成招募中状态
4期897212上市后
3期15613415关键试验
2期20317818剂量探索
1期67614安全性
来源:ClinicalTrials.gov via
search_clinical_trials
(intervention="metformin")
注册试验总数: 515项(截至2026-02-04) 主要研究适应症: 2型糖尿病(312项)、多囊卵巢综合征(87项)、癌症(45项)、肥胖症(38项)、非酒精性脂肪性肝病(33项)

Trial Outcomes Summary

试验结果摘要

  • Glycemic Control: Mean HbA1c reduction of 1.0-1.5% in monotherapy [★★★: NCT00123456]
  • Cardiovascular: UKPDS showed 39% reduction in MI risk [★★★: PMID:9742976]
  • Cancer Prevention: Mixed results; ongoing investigation [★★☆: NCT02019979]
Source:
extract_clinical_trial_outcomes
for NCT IDs listed

---
  • 血糖控制: 单药治疗使HbA1c平均降低1.0-1.5% [★★★: NCT00123456]
  • 心血管: UKPDS研究显示心梗风险降低39% [★★★: PMID:9742976]
  • 癌症预防: 结果不一;仍在研究中 [★★☆: NCT02019979]
来源:
extract_clinical_trial_outcomes
针对列出的NCT编号

---

Initial Report Template (Create This First)

初始报告模板(先创建此模板)

When starting research, immediately create this file before any tool calls:
File:
[DRUG]_drug_report.md
markdown
undefined
开始研究前,立即创建此文件,再进行任何工具调用:
文件:
[DRUG]_drug_report.md
markdown
undefined

Drug Research Report: [DRUG NAME]

药物研究报告: [药物名称]

Generated: [Date] | Query: [Original query] | Status: In Progress

生成日期: [日期] | 查询内容: [原始查询] | 状态: 进行中

Executive Summary

执行摘要

[Researching...]

[调研中...]

1. Compound Identity

1. 化合物身份

1.1 Database Identifiers

1.1 数据库标识符

[Researching...]
[调研中...]

1.2 Structural Information

1.2 结构信息

[Researching...]
[调研中...]

1.3 Names & Synonyms

1.3 名称与同义词

[Researching...]

[调研中...]

2. Chemical Properties

2. 化学特性

2.1 Physicochemical Profile

2.1 物理化学概况

[Researching...]
[调研中...]

2.2 Drug-Likeness Assessment

2.2 类药性评估

[Researching...]
[调研中...]

2.3 Solubility & Permeability

2.3 溶解度与渗透性

[Researching...]
[调研中...]

2.4 Salt Forms & Polymorphs

2.4 盐型与多晶型

[Researching...]
[调研中...]

2.5 Structure Visualization

2.5 结构可视化

[Researching...]

[调研中...]

3. Mechanism & Targets

3. 作用机制与靶点

3.1 Primary Mechanism of Action

3.1 主要作用机制

[Researching...]
[调研中...]

3.2 Primary Target(s)

3.2 主要靶点

[Researching...]
[调研中...]

3.3 Target Selectivity & Off-Targets

3.3 靶点选择性与脱靶效应

[Researching...]
[调研中...]

3.4 Bioactivity Profile (ChEMBL)

3.4 生物活性概况 (ChEMBL)

[Researching...]

[调研中...]

4. ADMET Properties

4. ADMET特性

4.1 Absorption

4.1 吸收

[Researching...]
[调研中...]

4.2 Distribution

4.2 分布

[Researching...]
[调研中...]

4.3 Metabolism

4.3 代谢

[Researching...]
[调研中...]

4.4 Excretion

4.4 排泄

[Researching...]
[调研中...]

4.5 Toxicity Predictions

4.5 毒性预测

[Researching...]

[调研中...]

5. Clinical Development

5. 临床开发

5.1 Development Status

5.1 开发状态

[Researching...]
[调研中...]

5.2 Clinical Trial Landscape

5.2 临床试验现状

[Researching...]
[调研中...]

5.3 Approved Indications

5.3 获批适应症

[Researching...]
[调研中...]

5.4 Investigational Indications

5.4 研究中适应症

[Researching...]
[调研中...]

5.5 Key Efficacy Data

5.5 关键疗效数据

[Researching...]
[调研中...]

5.6 Biomarkers & Companion Diagnostics

5.6 生物标志物与伴随诊断

[Researching...]

[调研中...]

6. Safety Profile

6. 安全性概况

6.1 Clinical Adverse Events

6.1 临床不良事件

[Researching...]
[调研中...]

6.2 Post-Marketing Safety (FAERS)

6.2 上市后安全性 (FAERS)

[Researching...]
[调研中...]

6.3 Black Box Warnings

6.3 黑框警告

[Researching...]
[调研中...]

6.4 Contraindications

6.4 禁忌症

[Researching...]
[调研中...]

6.5 Drug-Drug Interactions

6.5 药物相互作用

[Researching...]
[调研中...]

6.5.2 Drug-Food Interactions

6.5.2 药物-食物相互作用

[Researching...]
[调研中...]

6.6 Dose Modification Guidance

6.6 剂量调整指导

[Researching...]
[调研中...]

6.7 Drug Combinations & Regimens

6.7 药物联合与治疗方案

[Researching...]

[调研中...]

7. Pharmacogenomics

7. 药物基因组学

7.1 Relevant Pharmacogenes

7.1 相关药物基因

[Researching...]
[调研中...]

7.2 Clinical Annotations

7.2 临床注释

[Researching...]
[调研中...]

7.3 Dosing Guidelines (CPIC/DPWG)

7.3 给药指南 (CPIC/DPWG)

[Researching...]
[调研中...]

7.4 Actionable Variants

7.4 可操作变异

[Researching...]

[调研中...]

8. Regulatory & Labeling

8. 监管与标签

8.1 Approval Status

8.1 获批状态

[Researching...]
[调研中...]

8.2 Label Highlights

8.2 标签要点

[Researching...]
[调研中...]

8.3 Patents & Exclusivity

8.3 专利与独占权

[Researching...]
[调研中...]

8.4 Label Changes & Warnings

8.4 标签变更与警告

[Researching...]
[调研中...]

8.5 Special Populations

8.5 特殊人群

[Researching...]
[调研中...]

8.6 Regulatory Timeline & History

8.6 监管时间线与历史

[Researching...]

[调研中...]

9. Literature & Research Landscape

9. 文献与研究现状

9.1 Publication Metrics

9.1 发表指标

[Researching...]
[调研中...]

9.2 Research Themes

9.2 研究主题

[Researching...]
[调研中...]

9.3 Recent Key Publications

9.3 近期关键出版物

[Researching...]
[调研中...]

9.4 Real-World Evidence

9.4 真实世界证据

[Researching...]

[调研中...]

10. Conclusions & Assessment

10. 结论与评估

10.1 Drug Profile Scorecard

10.1 药物概况评分卡

[Researching...]
[调研中...]

10.2 Key Strengths

10.2 主要优势

[Researching...]
[调研中...]

10.3 Key Concerns/Limitations

10.3 主要关注/局限性

[Researching...]
[调研中...]

10.4 Research Gaps

10.4 研究空白

[Researching...]
[调研中...]

10.5 Comparative Analysis

10.5 对比分析

[Researching...]

[调研中...]

11. Data Sources & Methodology

11. 数据来源与方法学

11.1 Primary Data Sources

11.1 主要数据来源

[Researching...]
[调研中...]

11.2 Tool Call Summary

11.2 工具调用摘要

[Researching...]
[调研中...]

11.3 Quality Control Metrics

11.3 质量控制指标

[Researching...]

Then progressively replace `[Researching...]` with actual findings as you query each tool.

---
[调研中...]

然后在查询每个工具后,逐步用实际研究结果替换`[调研中...]`。

---

FDA Label Core Fields Bundle

FDA标签核心字段集合

For approved drugs, ALWAYS retrieve these FDA label sections early (after getting set_id from
DailyMed_search_spls
):
对于已获批药物,需尽早检索这些FDA标签章节(从
DailyMed_search_spls
获取set_id后):

Critical Label Sections

关键标签章节

Call
DailyMed_get_spl_sections_by_setid(setid=set_id, sections=[...])
with these sections:
Phase 1 (Mechanism & Chemistry):
  • mechanism_of_action
    → Section 3.1
  • pharmacodynamics
    → Section 3.1
  • chemistry
    → Section 2.4
Phase 2 (ADMET & PK):
  • clinical_pharmacology
    → Section 4
  • pharmacokinetics
    → Section 4.1-4.4
  • drug_interactions
    → Section 4.3, 6.5
Phase 3 (Safety & Dosing):
  • warnings_and_cautions
    → Section 6.3
  • adverse_reactions
    → Section 6.1
  • dosage_and_administration
    → Section 6.6, 8.2
Phase 4 (PGx & Clinical):
  • pharmacogenomics
    → Section 7
  • clinical_studies
    → Section 5.5
  • description
    → Section 2.5 (formulation)
  • inactive_ingredients
    → Section 2.5
调用
DailyMed_get_spl_sections_by_setid(setid=set_id, sections=[...])
时,包含以下章节:
阶段1(作用机制与化学):
  • mechanism_of_action
    → 第3.1节
  • pharmacodynamics
    → 第3.1节
  • chemistry
    → 第2.4节
阶段2(ADMET与药代动力学):
  • clinical_pharmacology
    → 第4节
  • pharmacokinetics
    → 第4.1-4.4节
  • drug_interactions
    → 第4.3、6.5节
阶段3(安全性与给药):
  • warnings_and_cautions
    → 第6.3节
  • adverse_reactions
    → 第6.1节
  • dosage_and_administration
    → 第6.6、8.2节
阶段4(药物基因组学与临床):
  • pharmacogenomics
    → 第7节
  • clinical_studies
    → 第5.5节
  • description
    → 第2.5节(制剂)
  • inactive_ingredients
    → 第2.5节

Label Extraction Strategy

标签提取策略

1. Get set_id: DailyMed_search_spls(drug_name)
   
2. Batch call for all core sections (or 3-4 calls with 4-5 sections each):
   DailyMed_get_spl_sections_by_setid(setid=set_id, sections=["mechanism_of_action", "pharmacodynamics", ...])
   
3. Extract and populate report sections as you retrieve data
This ensures you have authoritative FDA-approved information even if prediction tools fail.

1. 获取set_id: DailyMed_search_spls(drug_name)
   
2. 批量调用所有核心章节(或分3-4次调用,每次4-5个章节):
   DailyMed_get_spl_sections_by_setid(setid=set_id, sections=["mechanism_of_action", "pharmacodynamics", ...])
   
3. 检索数据后,提取并填充报告章节
即使预测工具失效,这也能确保你拥有权威的FDA获批信息。

Compound Disambiguation (Phase 1)

化合物消歧(阶段1)

CRITICAL: Establish compound identity before any research.
关键: 开展任何研究前,先确定化合物身份。

Identifier Resolution Chain

标识符解析链

1. PubChem_get_CID_by_compound_name(compound_name)
   └─ Extract: CID, canonical SMILES, formula
   
2. ChEMBL_search_compounds(query=drug_name)
   └─ Extract: ChEMBL ID, pref_name
   
3. DailyMed_search_spls(drug_name)
   └─ Extract: Set ID, NDC codes (if approved)
   
4. PharmGKB_search_drugs(query=drug_name)
   └─ Extract: PharmGKB ID (PA...)
1. PubChem_get_CID_by_compound_name(compound_name)
   └─ 提取: CID、标准SMILES、分子式
   
2. ChEMBL_search_compounds(query=drug_name)
   └─ 提取: ChEMBL ID、首选名称
   
3. DailyMed_search_spls(drug_name)
   └─ 提取: Set ID、NDC编码(若已获批)
   
4. PharmGKB_search_drugs(query=drug_name)
   └─ 提取: PharmGKB ID (PA...)

Handle Naming Ambiguity

处理命名歧义

IssueExampleResolution
Salt formsmetformin vs metformin HClNote all CIDs; use parent compound
Isomersomeprazole vs esomeprazoleVerify SMILES; separate entries if distinct
Prodrugsenalapril vs enalaprilatDocument both; note conversion
Brand confusionDifferent products same nameClarify with user

问题示例解决方法
盐型差异metformin vs metformin HCl记录所有CID;使用母化合物
异构体omeprazole vs esomeprazole验证SMILES;若不同则分开记录
前药enalapril vs enalaprilat记录两者;注明转化关系
品牌混淆不同产品同名向用户确认

Tool Chains by Research Path

按研究路径划分的工具链

PATH 1: Chemical Properties & CMC

路径1: 化学特性与CMC

Objective: Full physicochemical profile, salt forms, formulation details
Multi-Step Chain:
1. PubChem_get_compound_properties_by_CID(cid)
   └─ Extract: MW, formula, XLogP, TPSA, HBD, HBA, rotatable bonds
   
2. ADMETAI_predict_physicochemical_properties(smiles=[smiles])
   └─ Extract: MW, logP, HBD, HBA, Lipinski, QED, stereo_centers, TPSA
   
3. ADMETAI_predict_solubility_lipophilicity_hydration(smiles=[smiles])
   └─ Extract: Solubility_AqSolDB, Lipophilicity_AstraZeneca

4. DailyMed_search_spls(drug_name)
   └─ Extract SPL set_id, then:
   
5. DailyMed_get_spl_sections_by_setid(setid=set_id, sections=["chemistry"])
   └─ Extract: Salt forms, polymorphs, molecular formula, structure diagram
   
6. DailyMed_get_spl_sections_by_setid(setid=set_id, sections=["description", "inactive_ingredients"])
   └─ Extract: Formulation details, excipients, dosage forms

7. FORMULATION COMPARISON (if multiple formulations exist):
   a. DailyMed_search_spls(drug_name) → identify all formulations (IR, ER, XR, etc.)
   b. For each formulation:
      - DailyMed_parse_clinical_pharmacology(setid) → extract PK parameters
      - Parse: Tmax, Cmax, AUC, half-life
   c. Create comparison table showing bioavailability differences
Type Normalization: Convert all numeric IDs to strings before API calls.
Output for Report:
markdown
undefined
目标: 完整的物理化学概况、盐型、制剂细节
多步骤链:
1. PubChem_get_compound_properties_by_CID(cid)
   └─ 提取: 分子量、分子式、XLogP、TPSA、氢键供体、氢键受体、可旋转键
   
2. ADMETAI_predict_physicochemical_properties(smiles=[smiles])
   └─ 提取: 分子量、logP、氢键供体、氢键受体、Lipinski规则、QED、手性中心、TPSA
   
3. ADMETAI_predict_solubility_lipophilicity_hydration(smiles=[smiles])
   └─ 提取: Solubility_AqSolDB、Lipophilicity_AstraZeneca

4. DailyMed_search_spls(drug_name)
   └─ 提取SPL set_id,然后:
   
5. DailyMed_get_spl_sections_by_setid(setid=set_id, sections=["chemistry"])
   └─ 提取: 盐型、多晶型、分子式、结构示意图
   
6. DailyMed_get_spl_sections_by_setid(setid=set_id, sections=["description", "inactive_ingredients"])
   └─ 提取: 制剂细节、辅料、剂型

7. 制剂对比(若存在多种制剂):
   a. DailyMed_search_spls(drug_name) → 识别所有制剂(IR、ER、XR等)
   b. 针对每种制剂:
      - DailyMed_parse_clinical_pharmacology(setid) → 提取药代动力学参数
      - 解析: Tmax、Cmax、AUC、半衰期
   c. 创建对比表格,展示生物利用度差异
类型归一化: API调用前,将所有数值ID转换为字符串。
报告输出示例:
markdown
undefined

2.1 Physicochemical Profile

2.1 物理化学概况

PropertyValueDrug-LikenessSource
Molecular Weight129.16 g/mol✓ (< 500)PubChem
LogP-2.64✓ (< 5)ADMET-AI
TPSA91.5 Ų✓ (< 140)PubChem
H-Bond Donors2✓ (≤ 5)PubChem
H-Bond Acceptors5✓ (< 10)PubChem
Rotatable Bonds2✓ (< 10)PubChem
pKa12.4 (basic)-DailyMed Label
Solubility300 mg/mL (water)HighDailyMed Label
Lipinski Rule of Five: ✓ PASS (0 violations) QED Score: 0.74 (Good drug-likeness)
Sources: PubChem via
PubChem_get_compound_properties_by_CID
, ADMET-AI via
ADMETAI_predict_physicochemical_properties
特性数值类药性来源
分子量129.16 g/mol✓ (< 500)PubChem
LogP-2.64✓ (< 5)ADMET-AI
TPSA91.5 Ų✓ (< 140)PubChem
氢键供体2✓ (≤ 5)PubChem
氢键受体5✓ (< 10)PubChem
可旋转键2✓ (< 10)PubChem
pKa12.4(碱性)-DailyMed标签
溶解度300 mg/mL(水)DailyMed标签
Lipinski五规则: ✓ 符合(0项违反) QED评分: 0.74(类药性良好)
来源: PubChem via
PubChem_get_compound_properties_by_CID
, ADMET-AI via
ADMETAI_predict_physicochemical_properties

2.4 Salt Forms & Polymorphs

2.4 盐型与多晶型

Marketed Form: Metformin hydrochloride (CID: 14219) Parent Compound: Metformin free base (CID: 4091)
Source: DailyMed SPL via
DailyMed_get_spl_sections_by_setid
(chemistry section)
上市剂型: 盐酸二甲双胍 (CID: 14219) 母化合物: 二甲双胍游离碱 (CID: 4091)
来源: DailyMed SPL via
DailyMed_get_spl_sections_by_setid
(化学章节)

2.5 Structure Visualization

2.5 结构可视化

2D Structure
Source: PubChem structure service
2D结构
来源: PubChem结构服务

2.6 Formulation Comparison (If Multiple Formulations Available)

2.6 制剂对比(若存在多种制剂)

FormulationTmax (h)Cmax (ng/mL)AUC (ng·h/mL)Half-life (h)Dosing
IR (Immediate Release)2.5120084006.5500 mg TID
ER (Extended Release)7.095089006.51000 mg QD
XR (Modified Release)4.0110092007.0750 mg BID
Formulation Insights:
  • ER formulation reduces Cmax by ~20% but maintains similar AUC
  • Once-daily ER dosing improves adherence vs TID IR
  • Food effect: High-fat meal increases ER absorption by 30%
Source: DailyMed clinical pharmacology sections for each formulation
undefined
制剂Tmax (h)Cmax (ng/mL)AUC (ng·h/mL)半衰期 (h)给药方案
IR(速释)2.5120084006.5500 mg 每日3次
ER(缓释)7.095089006.51000 mg 每日1次
XR(调释)4.0110092007.0750 mg 每日2次
制剂见解:
  • ER制剂使Cmax降低约20%,但AUC相似
  • 每日1次ER给药相比每日3次IR给药,患者依从性更高
  • 食物影响: 高脂餐使ER吸收增加30%
来源: 各制剂对应的DailyMed临床药理学章节
undefined

PATH 2: Mechanism & Targets

路径2: 作用机制与靶点

Objective: FDA label MOA + experimental targets + selectivity
Multi-Step Chain:
1. DailyMed_search_spls(drug_name) → get set_id
   
2. DailyMed_get_spl_sections_by_setid(setid=set_id, sections=["mechanism_of_action", "pharmacodynamics"])
   └─ Extract: Official FDA MOA description [★★★]
   
3. ChEMBL_search_activities(molecule_chembl_id=chembl_id, limit=100)
   └─ Extract: Activity records with target_chembl_id, pChEMBL, standard_type
   └─ Parse unique target_chembl_id values (convert to strings)
   
4. ChEMBL_get_target(target_chembl_id) for each unique target
   └─ Extract: Target name, UniProt ID, organism [★★★]
   
5. DGIdb_get_drug_info(drugs=[drug_name])
   └─ Extract: Target genes, interaction types, sources [★★☆]
   
6. PubChem_get_bioactivity_summary_by_CID(cid)
   └─ Extract: Assay summary, active/inactive counts [★★☆]
CRITICAL:
  • Avoid
    ChEMBL_get_molecule_targets
    - it returns unfiltered targets including irrelevant entries
  • Derive targets from activities instead: Filter to potent activities (pChEMBL ≥ 6.0 or IC50/EC50 ≤ 1 µM)
  • Type normalization: Convert all ChEMBL IDs to strings before API calls
Output for Report:
markdown
undefined
目标: FDA标签作用机制 + 实验靶点 + 选择性
多步骤链:
1. DailyMed_search_spls(drug_name) → 获取set_id
   
2. DailyMed_get_spl_sections_by_setid(setid=set_id, sections=["mechanism_of_action", "pharmacodynamics"])
   └─ 提取: 官方FDA作用机制描述 [★★★]
   
3. ChEMBL_search_activities(molecule_chembl_id=chembl_id, limit=100)
   └─ 提取: 包含target_chembl_id、pChEMBL、standard_type的活性记录
   └─ 解析唯一的target_chembl_id值(转换为字符串)
   
4. 针对每个唯一靶点调用ChEMBL_get_target(target_chembl_id)
   └─ 提取: 靶点名称、UniProt ID、物种 [★★★]
   
5. DGIdb_get_drug_info(drugs=[drug_name])
   └─ 提取: 靶基因、相互作用类型、来源 [★★☆]
   
6. PubChem_get_bioactivity_summary_by_CID(cid)
   └─ 提取: 实验摘要、活性/非活性计数 [★★☆]
关键注意事项:
  • 避免使用
    ChEMBL_get_molecule_targets
    - 该工具返回未过滤的靶点,包括无关条目
  • 从活性数据推导靶点: 筛选强效活性(pChEMBL ≥ 6.0 或 IC50/EC50 ≤ 1 µM)
  • 类型归一化: API调用前,将所有ChEMBL ID转换为字符串
报告输出示例:
markdown
undefined

3.1 Primary Mechanism of Action

3.1 主要作用机制

FDA Label MOA: Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Its pharmacologic mechanisms of action are different from other classes of oral antihyperglycemic agents. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Source: DailyMed SPL via
DailyMed_get_spl_sections_by_setid
(mechanism_of_action) [★★★]
FDA标签作用机制: 二甲双胍是一种抗高血糖药物,可改善2型糖尿病患者的葡萄糖耐量,降低基础和餐后血糖。其药理作用机制与其他口服抗高血糖药物不同。二甲双胍减少肝脏葡萄糖生成,降低肠道葡萄糖吸收,并通过增加外周组织对葡萄糖的摄取和利用来提高胰岛素敏感性。
来源: DailyMed SPL via
DailyMed_get_spl_sections_by_setid
(mechanism_of_action章节) [★★★]

3.2 Primary Target(s)

3.2 主要靶点

TargetUniProtTypePotencyAssaysEvidenceSource
PRKAA1 (AMPK α1)Q13131ActivatorEC50 ~10 µM12★★★ChEMBL
PRKAA2 (AMPK α2)P54646ActivatorEC50 ~15 µM8★★★ChEMBL
SLC22A1 (OCT1)O15245SubstrateKm ~1.5 mM5★★☆DGIdb
Source: ChEMBL via
ChEMBL_search_activities
ChEMBL_get_target
(filtered to pChEMBL ≥ 6.0)
靶点UniProt类型效价实验数证据等级来源
PRKAA1 (AMPK α1)Q13131激活剂EC50 ~10 µM12★★★ChEMBL
PRKAA2 (AMPK α2)P54646激活剂EC50 ~15 µM8★★★ChEMBL
SLC22A1 (OCT1)O15245底物Km ~1.5 mM5★★☆DGIdb
来源: ChEMBL via
ChEMBL_search_activities
ChEMBL_get_target
(筛选pChEMBL ≥ 6.0的条目)

3.3 Target Selectivity & Off-Targets

3.3 靶点选择性与脱靶效应

Selectivity Profile: Highly selective for AMPK family; no significant off-target binding at therapeutic concentrations.
Off-Target Activity (pChEMBL < 6.0):
  • Complex I (NADH dehydrogenase): IC50 ~1 mM [★★☆]
  • Weak inhibition; clinically relevant only at high doses
Source: ChEMBL activity analysis
选择性概况: 对AMPK家族高度选择性;治疗浓度下无显著脱靶结合。
脱靶活性 (pChEMBL < 6.0):
  • 复合物I(NADH脱氢酶): IC50 ~1 mM [★★☆]
  • 弱抑制;仅在高剂量下具有临床相关性
来源: ChEMBL活性分析

3.4 Bioactivity Profile

3.4 生物活性概况

Total ChEMBL Activities: 847 datapoints across 234 assays
  • Potency Range: IC50/EC50 from 1 µM to 10 mM
  • Primary Activity: AMPK activation (kinase assays)
  • Secondary Activities: Mitochondrial complex I inhibition
Source:
ChEMBL_search_activities
(CHEMBL1431)
undefined
ChEMBL总活性数据: 234项实验中的847个数据点
  • 效价范围: IC50/EC50 从1 µM到10 mM
  • 主要活性: AMPK激活(激酶实验)
  • 次要活性: 线粒体复合物I抑制
来源:
ChEMBL_search_activities
(CHEMBL1431)
undefined

PATH 3: ADMET Properties

路径3: ADMET特性

Objective: Full ADMET profile - predictions + FDA label PK
Multi-Step Chain (Primary - ADMET-AI):
1. ADMETAI_predict_bioavailability(smiles=[smiles])
   └─ Extract: Bioavailability_Ma, HIA_Hou, PAMPA_NCATS, Caco2_Wang, Pgp_Broccatelli
   
2. ADMETAI_predict_BBB_penetrance(smiles=[smiles])
   └─ Extract: BBB_Martins (0-1 probability)
   
3. ADMETAI_predict_CYP_interactions(smiles=[smiles])
   └─ Extract: CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4 (inhibitor/substrate)
   
4. ADMETAI_predict_clearance_distribution(smiles=[smiles])
   └─ Extract: Clearance, Half_Life_Obach, VDss_Lombardo, PPBR_AZ
   
5. ADMETAI_predict_toxicity(smiles=[smiles])
   └─ Extract: AMES, hERG, DILI, ClinTox, LD50_Zhu, Carcinogens
Fallback Chain (If ADMET-AI Fails):
6. DailyMed_get_spl_sections_by_setid(setid=set_id, sections=["clinical_pharmacology", "pharmacokinetics"])
   └─ Extract: Absorption, distribution, metabolism, excretion from label [★★★]
   
7. DailyMed_get_spl_sections_by_setid(setid=set_id, sections=["drug_interactions"])
   └─ Extract: CYP interactions, transporter interactions [★★★]
   
8. PubMed_search_articles(query="[drug] pharmacokinetics", max_results=10)
   └─ Extract: PK parameters from clinical studies [★★☆]
CRITICAL Dependency Gate:
  • If ADMET-AI tools fail (invalid SMILES, API error, validation error), automatically switch to fallback
  • Do NOT leave Section 4 as "predictions unavailable"
  • Always populate Section 4 with either predictions OR label data OR literature PK
Output for Report:
markdown
undefined
目标: 完整的ADMET概况 - 预测数据 + FDA标签药代动力学
多步骤链(主链 - ADMET-AI):
1. ADMETAI_predict_bioavailability(smiles=[smiles])
   └─ 提取: Bioavailability_Ma、HIA_Hou、PAMPA_NCATS、Caco2_Wang、Pgp_Broccatelli
   
2. ADMETAI_predict_BBB_penetrance(smiles=[smiles])
   └─ 提取: BBB_Martins(0-1概率)
   
3. ADMETAI_predict_CYP_interactions(smiles=[smiles])
   └─ 提取: CYP1A2、CYP2C9、CYP2C19、CYP2D6、CYP3A4(抑制剂/底物)
   
4. ADMETAI_predict_clearance_distribution(smiles=[smiles])
   └─ 提取: 清除率、Half_Life_Obach、VDss_Lombardo、PPBR_AZ
   
5. ADMETAI_predict_toxicity(smiles=[smiles])
   └─ 提取: AMES、hERG、DILI、ClinTox、LD50_Zhu、致癌物
备用链(若ADMET-AI失效):
6. DailyMed_get_spl_sections_by_setid(setid=set_id, sections=["clinical_pharmacology", "pharmacokinetics"])
   └─ 提取: 标签中的吸收、分布、代谢、排泄信息 [★★★]
   
7. DailyMed_get_spl_sections_by_setid(setid=set_id, sections=["drug_interactions"])
   └─ 提取: CYP相互作用、转运体相互作用 [★★★]
   
8. PubMed_search_articles(query="[drug] pharmacokinetics", max_results=10)
   └─ 提取: 临床研究中的药代动力学参数 [★★☆]
关键依赖门限:
  • 若ADMET-AI工具失效(SMILES无效、API错误、验证错误),自动切换至备用链
  • 不得将第4节留空为“预测数据不可用”
  • 必须用预测数据、标签数据或文献药代动力学数据填充第4节
报告输出示例:
markdown
undefined

4.1 Absorption

4.1 吸收

EndpointPredictionInterpretation
Oral Bioavailability0.72Good (>50%)
Human Intestinal Absorption0.89High
Caco-2 Permeability-5.2 (log cm/s)Moderate
PAMPA0.34Low-moderate
P-gp Substrate0.23Unlikely substrate
Source: ADMET-AI via
ADMETAI_predict_bioavailability
终点预测值解读
口服生物利用度0.72良好 (>50%)
人体肠道吸收0.89
Caco-2渗透性-5.2 (log cm/s)中等
PAMPA0.34低-中等
P-糖蛋白底物0.23不太可能是底物
来源: ADMET-AI via
ADMETAI_predict_bioavailability

4.5 Toxicity Predictions

4.5 毒性预测

EndpointPredictionRisk Level
AMES Mutagenicity0.08Low risk
hERG Inhibition0.12Low risk
Hepatotoxicity (DILI)0.15Low risk
Clinical Toxicity0.21Low risk
LD502.8 (log mol/kg)Moderate
Source: ADMET-AI via
ADMETAI_predict_toxicity
Summary: Low predicted toxicity across all endpoints. Favorable safety profile.
undefined
终点预测值风险等级
AMES致突变性0.08低风险
hERG抑制0.12低风险
肝毒性 (DILI)0.15低风险
临床毒性0.21低风险
LD502.8 (log mol/kg)中等
来源: ADMET-AI via
ADMETAI_predict_toxicity
摘要: 所有终点的预测毒性均较低。安全性概况良好。
undefined

PATH 4: Clinical Trials

路径4: 临床试验

Objective: Complete clinical development picture with accurate phase counts
Multi-Step Chain:
1. search_clinical_trials(intervention=drug_name, pageSize=100)
   └─ Extract: Full result set with NCT IDs, phases, statuses, conditions
   
2. COMPUTE PHASE COUNTS from results:
   └─ Count by phase: Phase 1, Phase 2, Phase 3, Phase 4
   └─ Count by status: Completed, Recruiting, Active not recruiting, Terminated
   └─ Group by condition/indication (top 5)
   └─ Generate summary table
   
3. SELECT REPRESENTATIVE TRIALS:
   └─ Top 5 Phase 3 completed trials (by enrollment or recency)
   └─ Top 5 Phase 4 post-marketing trials
   └─ Top 3 recruiting trials
   
4. get_clinical_trial_conditions_and_interventions(nct_ids=[selected_ids])
   └─ Extract: Detailed conditions, interventions, arm groups
   
5. extract_clinical_trial_outcomes(nct_ids=[completed_phase3])
   └─ Extract: Primary outcomes, efficacy measures, p-values (if available)
   
6. extract_clinical_trial_adverse_events(nct_ids=[completed_ids])
   └─ Extract: Serious AEs, common AEs by organ system (if available)

7. fda_pharmacogenomic_biomarkers(drug_name=drug_name)
   └─ Extract: FDA-required biomarker testing, approved companion diagnostics [★★★]

8. DailyMed_get_spl_sections_by_setid(setid=set_id, sections=["indications_and_usage"])
   └─ Parse for: "testing required", "biomarker", "companion diagnostic", "genetic testing" [★★★]

9. PharmGKB_search_drugs(query=drug_name)
   └─ Extract: PharmGKB drug ID for response predictors

10. PharmGKB_get_clinical_annotations(drug_id=pharmgkb_id)
    └─ Extract: Response/toxicity biomarkers with clinical evidence levels [★★☆]
CRITICAL:
  • Section 5.2 must show actual counts by phase/status, NOT just a list of trials
  • Separate by primary indication when relevant (e.g., breast cancer vs non-breast cancer)
  • List representative trials, not all trials
  • Section 5.6 must document: FDA-required testing (T1), companion diagnostics devices (T1), response predictors (T2)
Output for Section 5.6:
markdown
undefined
目标: 完整的临床开发图景,包含准确的试验阶段计数
多步骤链:
1. search_clinical_trials(intervention=drug_name, pageSize=100)
   └─ 提取: 完整结果集,包含NCT编号、试验阶段、状态、适应症
   
2. 从结果中计算试验阶段计数:
   └─ 按阶段计数: 1期、2期、3期、4期
   └─ 按状态计数: 已完成、招募中、活跃但不招募、终止
   └─ 按适应症分组(前5项)
   └─ 生成摘要表格
   
3. 选择代表性试验:
   └─ 前5项已完成的3期试验(按入组人数或时间排序)
   └─ 前5项上市后4期试验
   └─ 前3项招募中的试验
   
4. get_clinical_trial_conditions_and_interventions(nct_ids=[selected_ids])
   └─ 提取: 详细适应症、干预措施、试验组
   
5. extract_clinical_trial_outcomes(nct_ids=[completed_phase3])
   └─ 提取: 主要终点、疗效指标、p值(若有)
   
6. extract_clinical_trial_adverse_events(nct_ids=[completed_ids])
   └─ 提取: 严重不良事件、按器官系统分类的常见不良事件(若有)

7. fda_pharmacogenomic_biomarkers(drug_name=drug_name)
   └─ 提取: FDA要求的生物标志物检测、获批伴随诊断 [★★★]

8. DailyMed_get_spl_sections_by_setid(setid=set_id, sections=["indications_and_usage"])
   └─ 解析: "需检测"、"生物标志物"、"伴随诊断"、"基因检测"相关内容 [★★★]

9. PharmGKB_search_drugs(query=drug_name)
   └─ 提取: 用于反应预测因子的PharmGKB药物ID

10. PharmGKB_get_clinical_annotations(drug_id=pharmgkb_id)
    └─ 提取: 具有临床证据等级的反应/毒性生物标志物 [★★☆]
关键注意事项:
  • 第5.2节必须显示按阶段/状态划分的实际计数,而非仅列出试验
  • 必要时按主要适应症分开(例如:乳腺癌 vs 非乳腺癌)
  • 列出代表性试验,而非所有试验
  • 第5.6节必须记录: FDA要求的检测(T1)、伴随诊断设备(T1)、反应预测因子(T2)
第5.6节输出示例:
markdown
undefined

5.6 Biomarkers & Companion Diagnostics

5.6 生物标志物与伴随诊断

FDA-Required Testing

FDA要求的检测

BiomarkerRequirement LevelApproved Test(s)Evidence
EGFR T790MRequired (NSCLC)cobas EGFR Mutation Test v2T1: ★★★
BRCA1/2Recommended (ovarian)BRACAnalysis CDxT1: ★★★
Source: FDA Table of Pharmacogenomic Biomarkers via
fda_pharmacogenomic_biomarkers
生物标志物要求等级获批检测方法证据等级
EGFR T790M必需(NSCLC)cobas EGFR突变检测v2T1: ★★★
BRCA1/2推荐(卵巢癌)BRACAnalysis CDxT1: ★★★
来源: FDA药物基因组学生物标志物表 via
fda_pharmacogenomic_biomarkers

Companion Diagnostics

伴随诊断

Device: cobas EGFR Mutation Test v2 (FDA-approved, PMA P150044)
Indication: Detection of EGFR exon 19 deletions and T790M mutations in NSCLC
Testing Required: Yes - label states "Select patients for osimertinib based on FDA-approved test"
Source: DailyMed SPL indications section
设备: cobas EGFR突变检测v2(FDA获批,PMA P150044)
适应症: 检测NSCLC患者的EGFR外显子19缺失和T790M突变
检测要求: 是 - 标签注明“基于FDA获批检测选择奥希替尼治疗的患者”
来源: DailyMed SPL适应症章节

Response Predictors (PharmGKB)

反应预测因子 (PharmGKB)

GeneVariantAssociationEvidence Level
EGFRT790MIncreased responseLevel 1A
EGFRC797SResistance mechanismLevel 2A
Source: PharmGKB via
PharmGKB_get_clinical_annotations
(PA166114513)
Clinical Impact: Biomarker testing is mandatory for therapy selection. ~60% of NSCLC patients have EGFR mutations; T790M develops in ~50% of patients with acquired resistance to 1st/2nd generation EGFR TKIs.
undefined
基因变异关联证据等级
EGFRT790M反应增强1A等级
EGFRC797S耐药机制2A等级
来源: PharmGKB via
PharmGKB_get_clinical_annotations
(PA166114513)
临床影响: 生物标志物检测是治疗选择的必需步骤。约60%的NSCLC患者存在EGFR突变;约50%的患者在对1/2代EGFR TKI产生获得性耐药后出现T790M突变。
undefined

PATH 5: Post-Marketing Safety & Drug Interactions

路径5: 上市后安全性与药物相互作用

Objective: Real-world safety signals + DDI guidance + dose modifications
Multi-Step Chain (FAERS):
1. FAERS_count_reactions_by_drug_event(medicinalproduct=drug_name)
   └─ Extract: Top 20 adverse reactions by MedDRA term [★★★]
   
2. FAERS_count_seriousness_by_drug_event(medicinalproduct=drug_name)
   └─ Extract: Serious vs non-serious counts & ratio [★★★]
   
3. FAERS_count_outcomes_by_drug_event(medicinalproduct=drug_name)
   └─ Extract: Recovered, recovering, fatal, unresolved counts [★★★]
   
4. FAERS_count_death_related_by_drug(medicinalproduct=drug_name)
   └─ Extract: Fatal outcome count [★★★]
   
5. FAERS_count_patient_age_distribution(medicinalproduct=drug_name)
   └─ Extract: Reports by age group [★★★]
Multi-Step Chain (Drug Interactions):
6. DailyMed_get_spl_sections_by_setid(setid=set_id, sections=["drug_interactions"])
   └─ Extract: DDI table, CYP interactions, contraindicated combinations [★★★]
   
7. DailyMed_get_spl_sections_by_setid(setid=set_id, sections=["dosage_and_administration", "warnings_and_cautions"])
   └─ Extract: Dose modification triggers (ALT/AST thresholds, renal/hepatic impairment, CYP3A inhibitor/inducer adjustments) [★★★]

8. DailyMed_get_spl_by_setid(setid=set_id)
   └─ Parse full XML for drug-food interactions:
   └─ Search sections: "drug_and_or_food_interactions", "food_effect"
   └─ Keywords: grapefruit, alcohol, food, meal, dairy, high-fat, fasting
   └─ Extract: effect magnitude, mechanism, recommendations [★★★]

9. search_clinical_trials(intervention=f"{drug_name} AND combination", pageSize=50)
   └─ Extract: Approved combinations, regimens, co-administration studies [★★★]

10. DailyMed_get_spl_sections_by_setid(setid=set_id, sections=["indications_and_usage", "dosage_and_administration"])
    └─ Parse for: "in combination with", "administered with", regimen details [★★★]
CRITICAL FAERS Reporting Requirements:
  • Include date window (e.g., "Reports from 2004-2026")
  • Report seriousness breakdown (not just top PTs)
  • Add limitations paragraph: Small N, voluntary reporting, causality not established, reporting bias
  • Note if data is unavailable or limited
Output for Report:
markdown
undefined
目标: 真实世界安全信号 + 药物相互作用指导 + 剂量调整
多步骤链(FAERS):
1. FAERS_count_reactions_by_drug_event(medicinalproduct=drug_name)
   └─ 提取: 按MedDRA术语排名前20的不良反应 [★★★]
   
2. FAERS_count_seriousness_by_drug_event(medicinalproduct=drug_name)
   └─ 提取: 严重与非严重事件计数及比例 [★★★]
   
3. FAERS_count_outcomes_by_drug_event(medicinalproduct=drug_name)
   └─ 提取: 恢复、好转、致命、未解决的计数 [★★★]
   
4. FAERS_count_death_related_by_drug(medicinalproduct=drug_name)
   └─ 提取: 致命结局计数 [★★★]
   
5. FAERS_count_patient_age_distribution(medicinalproduct=drug_name)
   └─ 提取: 按年龄组划分的报告数 [★★★]
多步骤链(药物相互作用):
6. DailyMed_get_spl_sections_by_setid(setid=set_id, sections=["drug_interactions"])
   └─ 提取: 药物相互作用表格、CYP相互作用、禁忌组合 [★★★]
   
7. DailyMed_get_spl_sections_by_setid(setid=set_id, sections=["dosage_and_administration", "warnings_and_cautions"])
   └─ 提取: 剂量调整触发因素(ALT/AST阈值、肾/肝功能损伤、CYP3A抑制剂/诱导剂调整) [★★★]

8. DailyMed_get_spl_by_setid(setid=set_id)
   └─ 解析完整XML以获取药物-食物相互作用:
   └─ 搜索章节: "drug_and_or_food_interactions"、"food_effect"
   └─ 关键词: 葡萄柚、酒精、食物、餐食、乳制品、高脂、空腹
   └─ 提取: 影响程度、机制、建议 [★★★]

9. search_clinical_trials(intervention=f"{drug_name} AND combination", pageSize=50)
   └─ 提取: 获批联合疗法、治疗方案、联合给药研究 [★★★]

10. DailyMed_get_spl_sections_by_setid(setid=set_id, sections=["indications_and_usage", "dosage_and_administration"])
    └─ 解析: "与...联合使用"、"与...同时给药"、治疗方案细节 [★★★]
FAERS报告关键要求:
  • 包含时间范围(例如:"2004-2026年报告")
  • 报告严重程度细分(不仅是前几位的首选术语)
  • 添加局限性段落: 样本量小、自愿报告、未确定因果关系、报告偏倚
  • 注明数据是否不可用或有限
报告输出示例:
markdown
undefined

6.2 Post-Marketing Safety (FAERS)

6.2 上市后安全性 (FAERS)

Total FAERS Reports: 45,234 (Date range: 2004Q1 - 2026Q1)
FAERS总报告数: 45,234份(时间范围: 2004Q1 - 2026Q1)

Seriousness Breakdown

严重程度细分

CategoryCountPercentage
Serious23,45651.8%
Non-Serious21,77848.2%
Source: FDA FAERS via
FAERS_count_seriousness_by_drug_event
类别计数百分比
严重23,45651.8%
非严重21,77848.2%
来源: FDA FAERS via
FAERS_count_seriousness_by_drug_event

Top Adverse Reactions

前5位不良反应

Reaction (MedDRA PT)Count% of Reports
Diarrhoea8,23418.2%
Nausea6,89215.2%
Lactic acidosis3,4567.6%
Vomiting2,9876.6%
Abdominal pain2,5435.6%
Source: FDA FAERS via
FAERS_count_reactions_by_drug_event
反应(MedDRA首选术语)计数占报告数百分比
腹泻8,23418.2%
恶心6,89215.2%
乳酸酸中毒3,4567.6%
呕吐2,9876.6%
腹痛2,5435.6%
来源: FDA FAERS via
FAERS_count_reactions_by_drug_event

Outcome Distribution

结局分布

OutcomeCountPercentage
Recovered/Resolved18,23440.3%
Not Recovered12,45627.5%
Fatal2,1344.7%
Unknown12,41027.4%
Source:
FAERS_count_outcomes_by_drug_event
结局计数百分比
恢复/解决18,23440.3%
未恢复12,45627.5%
致命2,1344.7%
未知12,41027.4%
来源:
FAERS_count_outcomes_by_drug_event

Data Limitations

数据局限性

FAERS data represents voluntary reports and has important limitations:
  • Small sample size relative to total prescriptions (N=45,234 reports)
  • Reporting bias: Serious events more likely to be reported
  • Causality not established: Reports do not prove drug caused the event
  • Incomplete data: Many reports lack outcome information (27.4%)
Signal Assessment: Lactic acidosis signal consistent with known labeling. GI events expected class effect.
FAERS数据为自愿报告,存在重要局限性:
  • 样本量小 相对于总处方量(N=45,234份报告)
  • 报告偏倚: 严重事件更易被报告
  • 未确定因果关系: 报告并不证明药物导致事件
  • 数据不完整: 许多报告缺乏结局信息(27.4%)
信号评估: 乳酸酸中毒信号与已知标签一致。胃肠道事件为预期的类效应。

6.6 Dose Modification Guidance

6.6 剂量调整指导

Hepatic Impairment

肝功能损伤

ALT/AST LevelAction
ALT >3× ULNHold dose; reassess liver function
ALT >5× ULNDiscontinue permanently
Baseline cirrhosisNot recommended (Child-Pugh B/C)
ALT/AST水平措施
ALT >3× ULN暂停给药;重新评估肝功能
ALT >5× ULN永久停药
基线肝硬化不推荐使用(Child-Pugh B/C级)

Renal Impairment

肾功能损伤

eGFR (mL/min/1.73m²)Dosing
≥60No adjustment
45-59Reduce to 1000 mg/day max
30-44Reduce to 500 mg/day max
<30Contraindicated
eGFR (mL/min/1.73m²)给药方案
≥60无需调整
45-59最大剂量减至1000 mg/天
30-44最大剂量减至500 mg/天
<30禁忌使用

CYP3A Interaction Management

CYP3A相互作用管理

  • Strong CYP3A4 inhibitors (ketoconazole, clarithromycin): No dose adjustment (not CYP substrate)
  • Strong CYP3A4 inducers (rifampin, phenytoin): No dose adjustment
Source: DailyMed SPL via
DailyMed_get_spl_sections_by_setid
(dosage_and_administration, warnings)
  • 强CYP3A4抑制剂(酮康唑、克拉霉素): 无需调整剂量(非CYP底物)
  • 强CYP3A4诱导剂(利福平、苯妥英): 无需调整剂量
来源: DailyMed SPL via
DailyMed_get_spl_sections_by_setid
(dosage_and_administration、warnings章节)

6.5.2 Drug-Food Interactions

6.5.2 药物-食物相互作用

Food/BeverageEffectMechanismRecommendationSource
High-fat meal↑ Cmax 50%, ↑ AUC 30%Increased absorptionTake with food for consistencyLabel
Grapefruit juice↑ exposure (CYP3A4 substrate)CYP3A4 inhibitionAvoidLabel
Alcohol↑ CNS depressionAdditive effectLimit consumptionLabel
Source: DailyMed SPL via
DailyMed_get_spl_by_setid
(drug_and_or_food_interactions section)
Food Effect Summary: High-fat meals increase bioavailability; administer consistently with or without food. Avoid grapefruit products and limit alcohol.
食物/饮料影响机制建议来源
高脂餐↑ Cmax 50%, ↑ AUC 30%吸收增加随餐服用以保持一致性标签
葡萄柚汁↑ 暴露量(CYP3A4底物)CYP3A4抑制避免饮用标签
酒精↑ CNS抑制叠加效应限制摄入标签
来源: DailyMed SPL via
DailyMed_get_spl_by_setid
(drug_and_or_food_interactions章节)
食物影响摘要: 高脂餐增加生物利用度;需保持一致的给药方式(随餐或空腹)。避免葡萄柚制品,限制酒精摄入。

6.7 Drug Combinations & Regimens

6.7 药物联合与治疗方案

Approved Combination Therapies

获批联合疗法

CombinationIndicationRegimenTrialStatus
Drug A + fulvestrantER+/HER2- mBC400mg QD + fulv 500mg IMNCT03778931Approved
Drug A + palbociclibER+ advanced400mg QD + palbo 125mg (21/7)NCT04789031Phase 3
Source: ClinicalTrials.gov via
search_clinical_trials
联合方案适应症治疗方案试验状态
药物A + 氟维司群ER+/HER2- 转移性乳腺癌400mg 每日1次 + 氟维司群 500mg 肌注NCT03778931获批
药物A + 帕博西尼ER+ 晚期乳腺癌400mg 每日1次 + 帕博西尼 125mg(21天给药/7天停药)NCT047890313期
来源: ClinicalTrials.gov via
search_clinical_trials

Co-Administration Guidance

联合给药指导

With CDK4/6 Inhibitors:
  • Standard dosing (400 mg QD) maintained
  • Monitor QTc interval (additive effect possible)
  • No dose adjustment needed
With Fulvestrant:
  • Combination well-tolerated in EMERALD trial
  • No PK interaction observed
  • Standard dosing for both agents
Source: DailyMed SPL sections + trial protocols
Synergy Notes: Combination with CDK4/6 inhibitors shows additive benefit in preclinical models. Sequential therapy (CDK4/6i → SERD) common in clinical practice.
undefined
与CDK4/6抑制剂联用:
  • 维持标准剂量(400 mg 每日1次)
  • 监测QTc间期(可能存在叠加效应)
  • 无需调整剂量
与氟维司群联用:
  • EMERALD试验显示联合疗法耐受性良好
  • 未观察到药代动力学相互作用
  • 两种药物均使用标准剂量
来源: DailyMed SPL章节 + 试验方案
协同作用说明: 与CDK4/6抑制剂联用在临床前模型中显示叠加获益。临床实践中常见序贯治疗(CDK4/6i → SERD)。
undefined

PATH 6: Pharmacogenomics

路径6: 药物基因组学

Objective: PGx associations and dosing guidelines
Multi-Step Chain (Primary - PharmGKB):
1. PharmGKB_search_drugs(query=drug_name)
   └─ Extract: PharmGKB drug ID
   
2. PharmGKB_get_drug_details(drug_id)
   └─ Extract: Cross-references, related genes
   
3. PharmGKB_get_clinical_annotations(gene_id)  # For each related gene
   └─ Extract: Variant-drug associations, evidence levels
   
4. PharmGKB_get_dosing_guidelines(gene=gene_symbol)
   └─ Extract: CPIC/DPWG guideline recommendations
Fallback Chain (If PharmGKB Fails):
5. DailyMed_get_spl_sections_by_setid(setid=set_id, sections=["pharmacogenomics", "clinical_pharmacology"])
   └─ Extract: Label-based PGx information [★★★]
   
6. PubMed_search_articles(query="[drug] pharmacogenomics", max_results=5)
   └─ Extract: Published PGx associations [★★☆]
CRITICAL:
  • If PharmGKB tools fail (API error, timeout), switch to fallback
  • Document the failure and indicate "PharmGKB unavailable; using label + literature"
  • Always populate Section 7 with either PharmGKB data OR label data OR "No PGx associations identified"
Output for Report:
markdown
undefined
目标: 药物基因组学关联与给药指南
多步骤链(主链 - PharmGKB):
1. PharmGKB_search_drugs(query=drug_name)
   └─ 提取: PharmGKB药物ID
   
2. PharmGKB_get_drug_details(drug_id)
   └─ 提取: 交叉引用、相关基因
   
3. 针对每个相关基因调用PharmGKB_get_clinical_annotations(gene_id)
   └─ 提取: 变异-药物关联、证据等级
   
4. PharmGKB_get_dosing_guidelines(gene=gene_symbol)
   └─ 提取: CPIC/DPWG指南建议
备用链(若PharmGKB失效):
5. DailyMed_get_spl_sections_by_setid(setid=set_id, sections=["pharmacogenomics", "clinical_pharmacology"])
   └─ 提取: 基于标签的药物基因组学信息 [★★★]
   
6. PubMed_search_articles(query="[drug] pharmacogenomics", max_results=5)
   └─ 提取: 已发表的药物基因组学关联 [★★☆]
关键注意事项:
  • 若PharmGKB工具失效(API错误、超时),切换至备用链
  • 记录失效情况,并注明“PharmGKB不可用;使用标签 + 文献数据”
  • 必须用PharmGKB数据、标签数据或“未识别到药物基因组学关联”填充第7节
报告输出示例:
markdown
undefined

7.1 Relevant Pharmacogenes

7.1 相关药物基因

GeneRoleEvidence LevelSource
SLC22A1 (OCT1)Transporter (uptake)2APharmGKB
SLC22A2 (OCT2)Transporter (renal)2BPharmGKB
SLC47A1 (MATE1)Transporter (efflux)3PharmGKB
Source: PharmGKB via
PharmGKB_get_drug_details
基因作用证据等级来源
SLC22A1 (OCT1)转运体(摄取)2APharmGKB
SLC22A2 (OCT2)转运体(肾脏)2BPharmGKB
SLC47A1 (MATE1)转运体(外排)3PharmGKB
来源: PharmGKB via
PharmGKB_get_drug_details

7.3 Dosing Guidelines

7.3 给药指南

CPIC Guideline: No CPIC guideline currently available for metformin.
Clinical Annotations:
  • rs628031 (SLC22A1): Reduced metformin response in *4/*4 carriers
  • rs316019 (SLC22A2): May affect renal clearance
Source:
PharmGKB_get_clinical_annotations

---
CPIC指南: 目前无针对二甲双胍的CPIC指南。
临床注释:
  • rs628031 (SLC22A1): *4/*4携带者对二甲双胍反应降低
  • rs316019 (SLC22A2): 可能影响肾脏清除率
来源:
PharmGKB_get_clinical_annotations

---

PATH 7: Regulatory Status & Patents

路径7: 监管状态与专利

Objective: Comprehensive regulatory and intellectual property landscape
Multi-Step Chain:
1. DailyMed_search_spls(drug_name=drug_name)
   └─ Extract: SetID for regulatory label data

2. FDA_OrangeBook_search_drug(brand_name=drug_name)
   └─ Extract: Application number, approval dates [★★★]

3. FDA_OrangeBook_get_approval_history(appl_no=app_number)
   └─ Extract: Original approval date, supplements, label changes [★★★]

4. FDA_OrangeBook_get_exclusivity(brand_name=drug_name)
   └─ Extract: Exclusivity types (NCE, Pediatric, Orphan), expiration dates [★★★]

5. FDA_OrangeBook_get_patent_info(brand_name=drug_name)
   └─ Extract: Patent numbers, substance/formulation claims [★★★]

6. FDA_OrangeBook_check_generic_availability(brand_name=drug_name)
   └─ Extract: Generic entries, TE codes (AB rating), first generic date [★★★]

7. DailyMed_get_spl_sections_by_setid(setid=set_id, sections=["indications_and_usage"])
   └─ Parse for: breakthrough designation, priority review, orphan status [★★★]

8. DailyMed_get_spl_by_setid(setid=set_id)
   └─ Extract special populations sections (Section 8.5):
   └─ pediatric_use (LOINC 34076-0): age groups, dosing, safety
   └─ geriatric_use (LOINC 34082-8): efficacy, safety in elderly
   └─ pregnancy (LOINC 42228-7): risk summary, animal data, recommendations
   └─ nursing_mothers (LOINC 34080-2): lactation risk, recommendations
   └─ Extract: renal/hepatic dosing from dosage section [★★★]

9. Parse DailyMed SPL revision history for regulatory timeline (Section 8.6):
   └─ Initial approval date
   └─ Major label changes (safety updates, indication expansions)
   └─ PMR/PMC commitments from label [★★★]

10. Combine FDA_OrangeBook_get_approval_history + label data:
    └─ Create regulatory timeline table
    └─ Document approval pathway (priority, breakthrough, orphan)
    └─ Note limitation: US-only data [★★★]
CRITICAL:
  • Orange Book data is US-only; document limitation for EMA/PMDA
  • Patent expiration dates may not be directly available; calculate from approval + exclusivity periods
  • Document workaround: "Exact patent dates require Orange Book file download"
  • Special populations require XML parsing from full SPL (DailyMed_get_spl_by_setid)
  • Look for LOINC section codes to reliably extract special population data
Output for Section 8.3:
markdown
undefined
目标: 全面的监管与知识产权现状
多步骤链:
1. DailyMed_search_spls(drug_name=drug_name)
   └─ 提取: 用于监管标签数据的SetID

2. FDA_OrangeBook_search_drug(brand_name=drug_name)
   └─ 提取: 申请编号、获批日期 [★★★]

3. FDA_OrangeBook_get_approval_history(appl_no=app_number)
   └─ 提取: 原始获批日期、补充申请、标签变更 [★★★]

4. FDA_OrangeBook_get_exclusivity(brand_name=drug_name)
   └─ 提取: 独占权类型(NCE、儿科、孤儿药)、到期日期 [★★★]

5. FDA_OrangeBook_get_patent_info(brand_name=drug_name)
   └─ 提取: 专利号、物质/制剂权利要求 [★★★]

6. FDA_OrangeBook_check_generic_availability(brand_name=drug_name)
   └─ 提取: 仿制药条目、TE代码(AB评级)、首个仿制药获批日期 [★★★]

7. DailyMed_get_spl_sections_by_setid(setid=set_id, sections=["indications_and_usage"])
   └─ 解析: 突破性疗法认定、优先审评、孤儿药地位 [★★★]

8. DailyMed_get_spl_by_setid(setid=set_id)
   └─ 提取特殊人群章节(第8.5节):
   └─ pediatric_use (LOINC 34076-0): 年龄组、给药方案、安全性
   └─ geriatric_use (LOINC 34082-8): 疗效、老年患者安全性
   └─ pregnancy (LOINC 42228-7): 风险摘要、动物数据、建议
   └─ nursing_mothers (LOINC 34080-2): 泌乳风险、建议
   └─ 提取: 给药章节中的肾/肝功能损伤给药方案 [★★★]

9. 解析DailyMed SPL修订历史以获取监管时间线(第8.6节):
   └─ 初始获批日期
   └─ 主要标签变更(安全性更新、适应症扩展)
   └─ 标签中的PMR/PMC承诺 [★★★]

10. 结合FDA_OrangeBook_get_approval_history + 标签数据:
    └─ 创建监管时间线表格
    └─ 记录获批路径(优先审评、突破性疗法、孤儿药)
    └─ 注明局限性: 仅美国数据 [★★★]
关键注意事项:
  • Orange Book数据仅针对美国;需注明EMA/PMDA数据的局限性
  • 专利到期日期可能无法直接获取;从获批日期 + 独占权期限计算
  • 记录替代方法: "确切专利日期需下载Orange Book文件"
  • 特殊人群数据需从完整SPL(DailyMed_get_spl_by_setid)的XML解析获取
  • 查找LOINC章节代码以可靠提取特殊人群数据
第8.3节输出示例:
markdown
undefined

8.3 Patents & Exclusivity

8.3 专利与独占权

US Regulatory Status

美国监管状态

Application Number: NDA 213869
Original Approval: May 12, 2023
Approval Pathway:
  • Priority Review ✓
  • Breakthrough Therapy Designation ✓
  • Orphan Drug Status ✓
Source: FDA Orange Book via
FDA_OrangeBook_get_approval_history
申请编号: NDA 213869
原始获批日期: 2023年5月12日
获批路径:
  • 优先审评 ✓
  • 突破性疗法认定 ✓
  • 孤儿药地位 ✓
来源: FDA Orange Book via
FDA_OrangeBook_get_approval_history

Exclusivity Periods

独占权期限

TypeCodeExpiration DateProtections
New Chemical Entity (NCE)NMay 2028Blocks ANDA filing for 5 years
Orphan DrugOMay 2030Market exclusivity for indication
PediatricPNovember 2030+6 months extension
Source:
FDA_OrangeBook_get_exclusivity
Estimated Patent Cliff: ~2030 (based on NCE + Orphan + Pediatric exclusivity)
类型代码到期日期保护内容
新化学实体 (NCE)N2028年5月5年内阻止ANDA提交
孤儿药O2030年5月适应症市场独占权
儿科P2030年11月+6个月延长
来源:
FDA_OrangeBook_get_exclusivity
预计专利悬崖: ~2030年(基于NCE + 孤儿药 + 儿科独占权)

Patent Information

专利信息

Patent NumberSubstance/FormulationUse CodeExpiration
10,689,356SubstanceU-12037
11,123,456Crystal formU-22039
Source:
FDA_OrangeBook_get_patent_info
Note: Exact patent expiration dates require FDA Orange Book download; dates shown are estimates.
专利号物质/制剂使用代码到期日期
10,689,356物质U-12037年
11,123,456晶型U-22039年
来源:
FDA_OrangeBook_get_patent_info
: 确切专利到期日期需下载FDA Orange Book文件;所示日期为估算值。

Generic Availability

仿制药可用性

Generic Approved: No
First Generic Date: Not applicable
ANDA Applications: None approved
Source:
FDA_OrangeBook_check_generic_availability
Market Protection Summary: Drug is protected by NCE exclusivity until 2028, orphan exclusivity until 2030, and substance patents until 2037+. No generic competition expected before 2030.
Limitation: EMA and PMDA approval/patent data not available via public API.
仿制药获批: 否
首个仿制药日期: 不适用
ANDA申请: 无获批
来源:
FDA_OrangeBook_check_generic_availability
市场保护摘要: 药物受NCE独占权保护至2028年,孤儿药独占权至2030年,物质专利至2037年+。2030年前预计无仿制药竞争。
局限性: EMA和PMDA获批/专利数据无法通过公共API获取。

8.5 Special Populations

8.5 特殊人群

Pediatric Use

儿科使用

Age Groups Studied: Not established in pediatric patients
Dosing: No pediatric dosing recommendations available
Safety: Safety and efficacy not established in patients <18 years
Source: DailyMed SPL pediatric_use section (LOINC 34076-0)
研究年龄组: 未在儿科患者中确立
给药方案: 无儿科给药建议
安全性: 18岁以下患者的安全性和疗效未确立
来源: DailyMed SPL pediatric_use章节 (LOINC 34076-0)

Geriatric Use (≥65 years)

老年使用(≥65岁)

Population: 20% of clinical trial participants were ≥65 years
Efficacy: No overall differences in efficacy observed
Safety: Similar adverse event profile to younger adults
Dosing: No dose adjustment required
Source: DailyMed SPL geriatric_use section (LOINC 34082-8)
人群: 20%的临床试验参与者为≥65岁
疗效: 未观察到疗效的总体差异
安全性: 不良事件谱与年轻成人相似
给药方案: 无需调整剂量
来源: DailyMed SPL geriatric_use章节 (LOINC 34082-8)

Pregnancy (Category D / Pregnancy Class)

妊娠(D类 / 妊娠分类)

Risk Summary: Based on animal studies and mechanism of action, may cause fetal harm. Advise pregnant women of potential risk to fetus.
Animal Data:
  • Rats: Fetal toxicity observed at exposures ≥0.03× human dose
  • Rabbits: Embryo-fetal toxicity at ≥0.01× human dose
Human Data: No adequate and well-controlled studies in pregnant women
Recommendation: Verify pregnancy status prior to initiation. Advise use of effective contraception during treatment and for 1 week after final dose.
Source: DailyMed SPL pregnancy section (LOINC 42228-7)
风险摘要: 基于动物研究和作用机制,可能对胎儿造成伤害。建议妊娠妇女注意对胎儿的潜在风险。
动物数据:
  • 大鼠: 暴露量≥0.03×人体剂量时观察到胎儿毒性
  • 兔: 暴露量≥0.01×人体剂量时观察到胚胎-胎儿毒性
人体数据: 无针对妊娠妇女的充分且对照良好的研究
建议: 给药前确认妊娠状态。建议治疗期间及最后一剂后1周内使用有效避孕措施。
来源: DailyMed SPL pregnancy章节 (LOINC 42228-7)

Lactation

泌乳

Risk Summary: No data on presence in human milk, effects on breastfed infant, or milk production
Recommendation: Advise women not to breastfeed during treatment and for 1 week after final dose due to potential for serious adverse reactions in breastfed infants.
Source: DailyMed SPL nursing_mothers section (LOINC 34080-2)
风险摘要: 无关于药物是否存在于人乳、对母乳喂养婴儿的影响或产乳量的数据
建议: 建议妇女治疗期间及最后一剂后1周内不要母乳喂养,因为可能对母乳喂养婴儿造成严重不良反应。
来源: DailyMed SPL nursing_mothers章节 (LOINC 34080-2)

Renal Impairment

肾功能损伤

eGFR (mL/min/1.73m²)Dosing Recommendation
≥30 (mild-moderate)No dose adjustment required
<30 (severe)Not studied; use with caution
ESRD on dialysisNot recommended
eGFR (mL/min/1.73m²)给药建议
≥30(轻-中度)无需调整剂量
<30(重度)未研究;谨慎使用
透析患者ESRD不推荐使用

Hepatic Impairment

肝功能损伤

Child-Pugh ClassDosing Recommendation
A (mild)No dose adjustment required
B (moderate)Reduce dose to 258 mg once daily
C (severe)Not recommended
Source: DailyMed SPL dosage_and_administration section
Child-Pugh分级给药建议
A(轻度)无需调整剂量
B(中度)剂量减至258 mg 每日1次
C(重度)不推荐使用
来源: DailyMed SPL dosage_and_administration章节

8.6 Regulatory Timeline & History

8.6 监管时间线与历史

US FDA Timeline

美国FDA时间线

DateMilestoneNotes
2018-03IND filedPhase 1 initiated
2019-11Breakthrough Therapy DesignationFor ER+/HER2- mBC with ESR1 mutation
2020-02Phase 3 (EMERALD) initiatedvs fulvestrant
2022-08NDA submittedPriority Review granted
2023-01-27FDA approvalAccelerated approval pathway
Application Number: NDA 213869
Review Classification: Priority Review (6-month timeline)
Approval Pathway: Accelerated approval under Subpart H
Designation: Breakthrough Therapy, Orphan Drug
Source: FDA Orange Book + DailyMed label history
日期里程碑说明
2018-03提交IND启动1期试验
2019-11突破性疗法认定用于ER+/HER2- 转移性乳腺癌伴ESR1突变
2020-02启动3期试验(EMERALD)对比氟维司群
2022-08提交NDA授予优先审评
2023-01-27FDA获批加速获批路径
申请编号: NDA 213869
审评分类: 优先审评(6个月时间线)
获批路径: Subpart H下的加速获批
认定: 突破性疗法、孤儿药
来源: FDA Orange Book + DailyMed标签历史

Post-Marketing Requirements (PMRs)

上市后要求(PMRs)

PMRDescriptionDue DateStatus
PMR 1Confirmatory Phase 3 trial (EMERALD)2025-12Completed
PMR 2Pediatric assessment2028-06Ongoing
PMR描述截止日期状态
PMR 1确证性3期试验(EMERALD)2025-12已完成
PMR 2儿科评估2028-06进行中

Major Label Changes

主要标签变更

DateChange TypeSummary
2023-01-27Initial approvalER+/HER2- mBC, ESR1 mutation
2023-06-15Safety updateAdded hepatotoxicity monitoring
2024-02-01Indication expansionAdded post-CDK4/6i language
Source: DailyMed SPL revision history
Regulatory Pathway Summary: Received Breakthrough Therapy Designation (2019), Priority Review, and Accelerated Approval (2023). Confirmatory trial (EMERALD) successfully completed in 2025, converting to full approval.
Limitation: EMA and PMDA approval data not available via public API. US data only.

---
日期变更类型摘要
2023-01-27初始获批ER+/HER2- 转移性乳腺癌,ESR1突变
2023-06-15安全性更新添加肝毒性监测
2024-02-01适应症扩展添加CDK4/6i后治疗的表述
来源: DailyMed SPL修订历史
监管路径摘要: 获得突破性疗法认定(2019年)、优先审评和加速获批(2023年)。确证性试验(EMERALD)于2025年成功完成,转为完全获批。
局限性: EMA和PMDA获批数据无法通过公共API获取。仅美国数据。

---

PATH 8: Real-World Evidence

路径8: 真实世界证据

Objective: Complement clinical trial efficacy with real-world effectiveness data
Multi-Step Chain:
1. search_clinical_trials(study_type="OBSERVATIONAL", intervention=drug_name, pageSize=50)
   └─ Extract: RWE studies, registry trials, observational cohorts [★★★]

2. PubMed_search_articles(query=f"{drug_name} (real-world OR observational OR effectiveness)", max_results=20)
   └─ Extract: RWE publications, adherence studies, off-label use [★★☆]

3. PubMed_search_articles(query=f"{drug_name} (registry OR post-marketing OR surveillance)", max_results=10)
   └─ Extract: Post-marketing surveillance, long-term outcomes [★★☆]

4. Compare efficacy vs effectiveness:
   └─ Clinical trial primary outcomes vs real-world outcomes
   └─ Trial inclusion criteria vs real-world patient demographics
   └─ Adherence rates in trials vs clinical practice
Output for Section 9.4:
markdown
undefined
目标: 用真实世界有效性数据补充临床试验疗效
多步骤链:
1. search_clinical_trials(study_type="OBSERVATIONAL", intervention=drug_name, pageSize=50)
   └─ 提取: RWE研究、注册试验、观察性队列 [★★★]

2. PubMed_search_articles(query=f"{drug_name} (real-world OR observational OR effectiveness)", max_results=20)
   └─ 提取: RWE出版物、依从性研究、超说明书使用 [★★☆]

3. PubMed_search_articles(query=f"{drug_name} (registry OR post-marketing OR surveillance)", max_results=10)
   └─ 提取: 上市后监测、长期结局 [★★☆]

4. 对比疗效与有效性:
   └─ 临床试验主要终点 vs 真实世界结局
   └─ 试验纳入标准 vs 真实世界患者人群特征
   └─ 试验中依从性 vs 临床实践中依从性
第9.4节输出示例:
markdown
undefined

9.4 Real-World Evidence

9.4 真实世界证据

Observational Studies

观察性研究

Registry Trials: 12 ongoing, 8 completed
Key Studies:
  • ELEVATE Registry (NCT04857528): Real-world safety/effectiveness in 500+ ER+ breast cancer patients
  • Post-Marketing Surveillance: European Drug Monitoring (PASS required through 2027)
Source: ClinicalTrials.gov via
search_clinical_trials
(study_type="OBSERVATIONAL")
注册试验: 12项进行中,8项已完成
关键研究:
  • ELEVATE注册研究 (NCT04857528): 500+例ER+乳腺癌患者的真实世界安全性/有效性
  • 上市后监测: 欧洲药物监测(需PASS至2027年)
来源: ClinicalTrials.gov via
search_clinical_trials
(study_type="OBSERVATIONAL")

Real-World Effectiveness

真实世界有效性

OutcomeClinical Trial (Pivotal)Real-World StudyDifference
PFS (months)3.8 (EMERALD, N=478)3.2 (ELEVATE, N=312)-0.6 mo
Response rate19.2%16.5%-2.7%
Treatment duration5.4 mo4.1 mo-1.3 mo
Effectiveness Gap Analysis: Real-world PFS ~16% shorter than trial efficacy, likely due to:
  • Broader patient population (less restrictive than trial inclusion)
  • Higher discontinuation rates (AE intolerance, cost issues)
  • Sequential therapy effects (more prior lines than trial allowed)
Sources: PMID:34567890 (ELEVATE interim), PMID:35678901 (comparative effectiveness)
结局临床试验(关键)真实世界研究差异
PFS(月)3.8(EMERALD, N=478)3.2(ELEVATE, N=312)-0.6 月
缓解率19.2%16.5%-2.7%
治疗持续时间5.4 月4.1 月-1.3 月
有效性差距分析: 真实世界PFS比试验疗效短约16%,可能原因:
  • 更广泛的患者人群(纳入标准比试验宽松)
  • 更高的停药率(不良事件不耐受、费用问题)
  • 序贯治疗效应(比试验允许的先前治疗线数更多)
来源: PMID:34567890(ELEVATE中期数据)、PMID:35678901(对比有效性)

Adherence & Persistence

依从性与持续性

Mean Treatment Duration: 4.1 months (RWE) vs 5.4 months (trial)
Discontinuation Reasons (RWE cohort, N=312):
  • Progression: 58%
  • Adverse events: 28%
  • Patient preference/cost: 9%
  • Death: 5%
Adherence Rate: 73% (defined as MPR ≥0.8) in community oncology setting
Source: PMID:36789012 (US claims database analysis)
平均治疗持续时间: 4.1个月(RWE) vs 5.4个月(试验)
停药原因(RWE队列, N=312):
  • 疾病进展: 58%
  • 不良事件: 28%
  • 患者偏好/费用: 9%
  • 死亡: 5%
依从率: 73%(定义为MPR ≥0.8)在社区肿瘤学场景中
来源: PMID:36789012(美国医保数据库分析)

Off-Label Use

超说明书使用

Documented Off-Label Indications:
  • ER+ metastatic breast cancer, no prior endocrine therapy: 12% of prescriptions
  • Male breast cancer: 3% of prescriptions
  • Early breast cancer (neoadjuvant): < 1% (investigational)
Source: PubMed literature review
RWE Insights: Real-world data shows slightly lower effectiveness than pivotal trials but confirms benefit in broader patient population. Adherence challenges highlight need for AE management strategies.

---
已记录的超说明书适应症:
  • ER+转移性乳腺癌,无先前内分泌治疗: 12%的处方
  • 男性乳腺癌: 3%的处方
  • 早期乳腺癌(新辅助): <1%(研究中)
来源: PubMed文献综述
RWE见解: 真实世界数据显示有效性略低于关键试验,但证实了在更广泛患者人群中的获益。依从性挑战凸显了不良事件管理策略的必要性。

---

PATH 9: Comparative Analysis

路径9: 对比分析

Objective: Position drug within therapeutic class with head-to-head and indirect comparisons
Multi-Step Chain:
1. Identify comparator drugs:
   └─ User provides OR infer from indication + mechanism
   └─ Example: For elacestrant (ER degrader), comparators = fulvestrant, other SERDs

2. For each comparator, run abbreviated tool chain:
   a. PubChem_get_CID_by_compound_name(compound=comparator)
   b. ChEMBL_search_activities(chemblid=comparator_chemblid, target="ESR1", max_results=20)
      └─ Extract: Potency vs primary target
   c. search_clinical_trials(intervention=comparator, condition=indication, pageSize=20)
      └─ Extract: Phase 3 trial counts, approval status
   d. FAERS_count_reactions_by_drug_event(medicinalproduct=comparator)
      └─ Extract: Top 5 adverse events, seriousness ratio

3. Search for head-to-head trials:
   search_clinical_trials(intervention=f"{drug_name} AND {comparator}")
   └─ Extract: Direct comparison trials [★★★]

4. PubMed_search_articles(query=f"{drug_name} vs {comparator}", max_results=10)
   └─ Extract: Network meta-analyses, indirect comparisons [★★☆]

5. Create comparison tables across dimensions:
   └─ Potency, selectivity, ADMET, efficacy, safety, cost (if available)
Output for Section 10.5:
markdown
undefined
目标: 在治疗类别中定位药物,进行头对头和间接对比
多步骤链:
1. 确定对比药物:
   └─ 用户提供 或 从适应症 + 作用机制推断
   └─ 示例: 对于elacestrant(ER降解剂),对比药物 = fulvestrant、其他SERDs

2. 针对每个对比药物运行简化工具链:
   a. PubChem_get_CID_by_compound_name(compound=comparator)
   b. ChEMBL_search_activities(chemblid=comparator_chemblid, target="ESR1", max_results=20)
      └─ 提取: 与主要靶点的效价
   c. search_clinical_trials(intervention=comparator, condition=indication, pageSize=20)
      └─ 提取: 3期试验计数、获批状态
   d. FAERS_count_reactions_by_drug_event(medicinalproduct=comparator)
      └─ 提取: 前5位不良反应、严重事件比例

3. 搜索头对头试验:
   search_clinical_trials(intervention=f"{drug_name} AND {comparator}")
   └─ 提取: 直接对比试验 [★★★]

4. PubMed_search_articles(query=f"{drug_name} vs {comparator}", max_results=10)
   └─ 提取: 网络meta分析、间接对比 [★★☆]

5. 创建跨维度对比表格:
   └─ 效价、选择性、ADMET、疗效、安全性、费用(若有)
第10.5节输出示例:
markdown
undefined

10.5 Comparative Analysis

10.5 对比分析

Drug Class: Selective Estrogen Receptor Degraders (SERDs)

药物类别: 选择性雌激素受体降解剂 (SERDs)

Primary Comparators: Fulvestrant (approved), AZD9833 (investigational), GDC-9545 (investigational)
主要对比药物: Fulvestrant(获批)、AZD9833(研究中)、GDC-9545(研究中)

Potency Comparison

效价对比

DrugESR1 WT IC50ESR1 Y537S IC50SelectivitySource
Elacestrant48 nM77 nM> 100x vs other NRsChEMBL
Fulvestrant9 nM~50 nM (est)> 100xChEMBL
AZD98330.7 nM1.2 nM> 1000xLiterature
Potency Ranking: AZD9833 > Fulvestrant ≈ Elacestrant for WT; all active against Y537S
Sources: ChEMBL via
ChEMBL_search_activities
, PMID:33445678
药物ESR1 WT IC50ESR1 Y537S IC50选择性来源
Elacestrant48 nM77 nM>100x vs 其他核受体ChEMBL
Fulvestrant9 nM~50 nM(估算)>100xChEMBL
AZD98330.7 nM1.2 nM>1000x文献
效价排名: AZD9833 > Fulvestrant ≈ Elacestrant(野生型);所有药物对Y537S均有活性
来源: ChEMBL via
ChEMBL_search_activities
、PMID:33445678

Clinical Trial Landscape

临床试验现状

DrugPhase 3 TrialsPrimary IndicationApproval Status
Elacestrant2 completed, 1 ongoingER+/HER2- mBCApproved (US, 2023)
Fulvestrant15+ completedER+/HER2- mBCApproved (2002)
AZD98333 ongoingER+/HER2- mBCInvestigational
GDC-95452 ongoingER+/HER2- mBCInvestigational
Source: ClinicalTrials.gov
药物3期试验数主要适应症获批状态
Elacestrant2项已完成,1项进行中ER+/HER2- 转移性乳腺癌获批(美国,2023年)
Fulvestrant15+项已完成ER+/HER2- 转移性乳腺癌获批(2002年)
AZD98333项进行中ER+/HER2- 转移性乳腺癌研究中
GDC-95452项进行中ER+/HER2- 转移性乳腺癌研究中
来源: ClinicalTrials.gov

Safety Profile Comparison

安全性概况对比

DrugTop AE (% patients)Serious AE RateFatal Outcomes
ElacestrantNausea (35%), Fatigue (30%)51.8%4.7% (FAERS)
FulvestrantInjection site reaction (40%), Hot flash (28%)48.2%3.9% (FAERS)
Safety Differentiation: Elacestrant oral administration avoids injection site reactions but has higher GI AE rate.
Sources: FAERS via
FAERS_count_reactions_by_drug_event
, product labels
药物前位不良事件(%患者)严重不良事件率致命结局
Elacestrant恶心(35%)、疲劳(30%)51.8%4.7%(FAERS)
Fulvestrant注射部位反应(40%)、潮热(28%)48.2%3.9%(FAERS)
安全性差异: Elacestrant口服给药避免了注射部位反应,但胃肠道不良事件率更高。
来源: FAERS via
FAERS_count_reactions_by_drug_event
、产品标签

Head-to-Head Trials

头对头试验

EMERALD vs Fulvestrant:
  • Trial: NCT03778931 (Phase 3, N=478, completed)
  • PFS: 3.8 mo (elacestrant) vs 1.9 mo (fulvestrant) in ESR1-mutated subgroup (HR 0.55, p<0.001)
  • PFS: 2.2 mo vs 1.9 mo in overall population (HR 0.84, p=0.05)
Source:
extract_clinical_trial_outcomes
(NCT03778931)
EMERALD vs Fulvestrant:
  • 试验: NCT03778931(3期, N=478, 已完成)
  • PFS: 3.8月(elacestrant) vs 1.9月(fulvestrant)在ESR1突变亚组(HR 0.55, p<0.001)
  • PFS: 2.2月 vs 1.9月在总体人群(HR 0.84, p=0.05)
来源:
extract_clinical_trial_outcomes
(NCT03778931)

Differentiation Factors

差异化因素

FactorElacestrant AdvantageFulvestrant Advantage
RouteOral (QD)IM injection (Q4W after loading)
ESR1 mutant efficacy+100% PFS improvementLess data
Brain metastasesBBB penetration (preclinical)Poor CNS penetration
ApprovalBiomarker-selected (ESR1 mut)Broader indication
ExperienceLimited (1 yr post-approval)Extensive (20+ yrs)
Positioning: Elacestrant fills unmet need for oral SERD with superior efficacy in ESR1-mutated disease. Fulvestrant remains standard for ESR1 WT due to longer track record.

---
因素Elacestrant优势Fulvestrant优势
给药途径口服(每日1次)肌注(负荷剂量后每4周1次)
ESR1突变疗效PFS改善+100%数据较少
脑转移血脑屏障穿透(临床前)CNS穿透性差
获批范围生物标志物选择(ESR1突变)更广泛的适应症
临床经验有限(获批1年)丰富(20+年)
定位: Elacestrant填补了口服SERD的未满足需求,在ESR1突变疾病中疗效更优。Fulvestrant因更长的使用记录,仍是ESR1野生型的标准治疗。

---

Type Normalization & Error Prevention

类型归一化与错误预防

Common Validation Errors

常见验证错误

Many ToolUniverse tools require string inputs but may return integers or floats. Always convert IDs to strings.
Problem Examples:
  • ChEMBL target IDs:
    12345
    (int) → should be
    "12345"
    (str)
  • PubMed IDs:
    23456789
    (int) → should be
    "23456789"
    (str)
  • Clinical trial NCT IDs: sometimes parsed as numbers
许多ToolUniverse工具要求字符串输入,但可能返回整数浮点数。始终将ID转换为字符串。
问题示例:
  • ChEMBL靶点ID:
    12345
    (整数)→ 应改为
    "12345"
    (字符串)
  • PubMed ID:
    23456789
    (整数)→ 应改为
    "23456789"
    (字符串)
  • 临床试验NCT ID: 有时会被解析为数字

Type Normalization Helper

类型归一化辅助工具

Before calling any tool with ID parameters:
python
undefined
调用任何带ID参数的工具前:
python
undefined

Convert all IDs to strings

将所有ID转换为字符串

chembl_ids = [str(id) for id in chembl_ids] nct_ids = [str(id) for id in nct_ids] pmids = [str(id) for id in pmids]
undefined
chembl_ids = [str(id) for id in chembl_ids] nct_ids = [str(id) for id in nct_ids] pmids = [str(id) for id in pmids]
undefined

Pre-Call Checklist

调用前检查清单

Before each API call:
  • All ID parameters are strings
  • Lists contain strings, not ints/floats
  • No
    None
    or
    null
    values in required fields
  • Arrays are non-empty if required

每次API调用前:
  • 所有ID参数均为字符串
  • 列表包含字符串,而非整数/浮点数
  • 必填字段无
    None
    null
  • 若必填则数组非空

Evidence Grading System

证据分级系统

Evidence Tiers

证据等级

TierSymbolDescriptionExample
T1★★★Phase 3 RCT, meta-analysis, FDA approvalPivotal trial, label indication
T2★★☆Phase 1/2 trial, large case seriesDose-finding study
T3★☆☆In vivo animal, in vitro cellularMouse PK study
T4☆☆☆Review mention, computational predictionADMET-AI prediction
等级符号描述示例
T1★★★3期RCT、meta分析、FDA获批关键试验、标签适应症
T2★★☆1/2期试验、大样本病例系列剂量探索研究
T3★☆☆体内动物实验、体外细胞实验小鼠药代动力学研究
T4☆☆☆综述提及、计算预测ADMET-AI预测

Application in Report

在报告中的应用

markdown
Metformin reduces hepatic glucose output via AMPK activation [★★★: FDA Label].
Phase 3 trials demonstrated HbA1c reduction of 1.0-1.5% [★★★: NCT00123456].
Preclinical studies suggest anti-cancer properties [★☆☆: PMID:23456789].
ADMET-AI predicts low hERG liability (0.12) [☆☆☆: computational].
markdown
二甲双胍通过激活AMPK减少肝脏葡萄糖输出 [★★★: FDA标签]。
3期试验显示HbA1c降低1.0-1.5% [★★★: NCT00123456]。
临床前研究提示抗癌特性 [★☆☆: PMID:23456789]。
ADMET-AI预测hERG风险低(0.12) [☆☆☆: 计算预测]。

Per-Section Summary

每节摘要

Include evidence quality summary for each major section:
markdown
undefined
为每个主要章节添加证据质量摘要:
markdown
undefined

5. Clinical Development

5. 临床开发

Evidence Quality: Strong (156 Phase 3 trials, 203 Phase 2, 67 Phase 1) Data Confidence: High - mature clinical program with decades of data

---
证据质量: 强(156项3期试验、203项2期试验、67项1期试验) 数据置信度: 高 - 成熟的临床项目,拥有数十年数据

---

Section Completeness Checklist

章节完整性检查清单

Before finalizing any report, verify each section meets minimum requirements:
最终确定任何报告前,验证每个章节是否满足最低要求:

Section 1 (Identity) - Minimum Requirements

第1节(身份)- 最低要求

  • PubChem CID with link
  • ChEMBL ID with link (or "Not in ChEMBL")
  • Canonical SMILES
  • Molecular formula and weight
  • At least 3 brand names OR "Generic only"
  • Salt forms identified (or "Parent compound only")
  • PubChem CID及链接
  • ChEMBL ID及链接(或“未收录于ChEMBL”)
  • 标准SMILES
  • 分子式和分子量
  • 至少3个品牌名 或 “仅仿制药”
  • 已识别盐型(或“仅母化合物”)

Section 2 (Chemistry) - Minimum Requirements

第2节(化学)- 最低要求

  • 6+ physicochemical properties in table format (including pKa if available)
  • Lipinski rule assessment with pass/fail
  • QED score with interpretation
  • Solubility data (predicted or label-based)
  • Salt forms documented (or "Parent compound only")
  • 2D structure image embedded (PubChem link)
  • Formulation details if available (dosage forms, excipients)
  • 6+项物理化学特性,表格形式(若有pKa则包含)
  • Lipinski规则评估,标注通过/不通过
  • QED评分及解读
  • 溶解度数据(预测或基于标签)
  • 盐型记录(或“仅母化合物”)
  • 嵌入2D结构图片(PubChem链接)
  • 若有则包含制剂细节(剂型、辅料)

Section 3 (Mechanism) - Minimum Requirements

第3节(作用机制)- 最低要求

  • FDA label MOA text quoted (if approved drug) OR literature MOA summary
  • Primary mechanism described in 2-3 sentences
  • At least 1 primary target with UniProt ID
  • Activity type and potency (IC50/EC50/Ki) with assay count
  • Target selectivity table (including mutant forms if relevant, e.g., ESR1 Y537S for endocrine drugs)
  • Off-target activity addressed (or "Highly selective")
  • 引用FDA标签作用机制文本(若为获批药物) 或 文献作用机制摘要
  • 主要作用机制用2-3句话描述
  • 至少1个主要靶点及UniProt ID
  • 活性类型和效价(IC50/EC50/Ki)及实验数
  • 靶点选择性表格(若相关则包含突变体,例如:内分泌药物的ESR1 Y537S)
  • 提及脱靶活性(或“高度选择性”)

Section 4 (ADMET) - Minimum Requirements

第4节(ADMET)- 最低要求

  • All 5 subsections present (A, D, M, E, T)
  • Absorption: bioavailability + at least 2 other endpoints (predicted OR label PK)
  • Distribution: BBB + VDss or PPB (predicted OR label PK)
  • Metabolism: CYP substrate/inhibitor status for 3+ CYPs (predicted OR label DDI)
  • Excretion: clearance OR half-life (predicted OR label PK)
  • Toxicity: AMES + hERG + at least 1 other (predicted OR label warnings)
  • If ADMET-AI fails, fallback to FDA label PK sections (do NOT leave "predictions unavailable")
  • 所有5个小节均存在(吸收、分布、代谢、排泄、毒性)
  • 吸收: 生物利用度 + 至少2项其他终点(预测或基于标签的药代动力学)
  • 分布: 血脑屏障穿透性 + VDss或蛋白结合率(预测或基于标签的药代动力学)
  • 代谢: 3+种CYP酶的底物/抑制剂状态(预测或基于标签的药物相互作用)
  • 排泄: 清除率 或 半衰期(预测或基于标签的药代动力学)
  • 毒性: AMES + hERG + 至少1项其他(预测或基于标签的警告)
  • 若ADMET-AI失效,回退至FDA标签药代动力学章节(不得留空“预测数据不可用”)

Section 5 (Clinical) - Minimum Requirements

第5节(临床)- 最低要求

  • Development status clearly stated (Approved/Investigational/Preclinical)
  • Actual counts by phase/status in table format (NOT just representative trial list)
  • Indication breakdown by counts (e.g., "312 diabetes trials, 87 PCOS trials")
  • Approved indications with year (or "Not approved")
  • Representative trial list (top 5 Phase 3, top 3 recruiting) with clear labels
  • Key efficacy data with trial references (or "No outcome data available")
  • 明确说明开发状态(获批/研究中/临床前)
  • 按阶段/状态划分的实际计数,表格形式(而非仅列出代表性试验)
  • 按适应症划分的计数(例如:“312项糖尿病试验、87项PCOS试验”)
  • 获批适应症及年份(或“未获批”)
  • 代表性试验列表(前5项3期试验、前3项招募中试验),标注清晰
  • 带试验引用的关键疗效数据(或“无结局数据可用”)

Section 6 (Safety) - Minimum Requirements

第6节(安全性)- 最低要求

  • Top 5 adverse events with frequencies
  • FAERS seriousness breakdown (serious vs non-serious counts)
  • FAERS date window documented (e.g., "2004-2026")
  • FAERS limitations paragraph (small N, reporting bias, causality not established)
  • Black box warnings (or "None")
  • At least 3 drug-drug interactions with mechanism (CYP, transporter) OR "No significant interactions"
  • Dose modification triggers (ALT/AST thresholds, renal impairment, CYP inhibitor/inducer adjustments)
  • 前5位不良反应及发生率
  • FAERS严重程度细分(严重/非严重计数)
  • FAERS时间范围记录(例如:“2004-2026年”)
  • FAERS局限性段落(样本量小、报告偏倚、未确定因果关系)
  • 黑框警告(或“无”)
  • 至少3项药物相互作用及机制(CYP、转运体) 或 “无显著相互作用”
  • 剂量调整触发因素表格(ALT/AST阈值、肾/肝功能损伤、CYP抑制剂/诱导剂调整)

Section 7 (PGx) - Minimum Requirements

第7节(药物基因组学)- 最低要求

  • Pharmacogenes listed (or "None identified")
  • CPIC/DPWG guideline status (or "No guideline available")
  • At least 1 clinical annotation OR "No annotations identified"
  • If PharmGKB fails, fallback to label PGx sections + literature (document the failure)
  • 列出药物基因(或“未识别到”)
  • CPIC/DPWG指南状态(或“无可用指南”)
  • 至少1项临床注释 或 “未识别到注释”
  • 若PharmGKB失效,回退至标签药物基因组学章节 + 文献(记录失效情况)

Section 10 (Conclusions) - Minimum Requirements

第10节(结论)- 最低要求

  • 5-point scorecard covering: efficacy, safety, PK, druggability, competition
  • 3+ key strengths
  • 3+ key concerns/limitations
  • At least 2 research gaps identified

  • 5项标准的评分卡,涵盖: 疗效、安全性、药代动力学、类药性、竞争力
  • 3+项主要优势
  • 3+项主要关注/局限性
  • 至少2项研究空白

Drug Profile Scorecard Template

药物概况评分卡模板

Include in Section 10:
markdown
undefined
在第10节中包含:
markdown
undefined

10.1 Drug Profile Scorecard

10.1 药物概况评分卡

CriterionScore (1-5)Rationale
Efficacy Evidence5Multiple Phase 3 trials, decades of use
Safety Profile4Well-tolerated; lactic acidosis rare but serious
PK/ADMET4Good bioavailability; renal elimination
Target Validation4AMPK mechanism well-established
Competitive Position3First-line but many alternatives
Overall4.0Strong drug profile
Interpretation:
  • 5 = Excellent, 4 = Good, 3 = Moderate, 2 = Concerning, 1 = Poor

---
标准评分 (1-5)理由
疗效证据5多项3期试验,数十年使用经验
安全性概况4耐受性良好;乳酸酸中毒罕见但严重
药代动力学/ADMET4生物利用度良好;肾脏排泄
靶点验证4AMPK机制已充分确立
竞争地位3一线治疗但存在多种替代药物
总体4.0强药物概况
解读:
  • 5 = 优秀, 4 = 良好, 3 = 中等, 2 = 关注, 1 = 差

---

Automated Completeness Audit

自动化完整性审核

CRITICAL: Before finalizing the report, run this audit checklist and append findings to Section 11.
关键: 最终确定报告前,运行此审核清单并将结果附加至第11节。

Audit Process

审核流程

  1. Review each section against minimum requirements (see Section Completeness Checklist)
  2. Flag any missing data with specific tool call recommendations
  3. Document tool failures and fallback attempts
  4. Generate completeness score (% of minimum requirements met)
  1. 对照最低要求审查每个章节(见章节完整性检查清单)
  2. 标记任何缺失数据,并给出具体工具调用建议
  3. 记录工具失效情况及备用尝试
  4. 生成完整性评分(满足最低要求的百分比)

Audit Output Template

审核输出模板

Add this to Section 11 (Data Sources & Methodology):
markdown
---
将此添加至第11节(数据来源与方法学):
markdown
---

Report Completeness Audit

报告完整性审核

Overall Completeness: 85% (17/20 minimum requirements met)
总体完整性: 85%(20项最低要求中满足17项)

Missing Data Items

缺失数据项

SectionMissing ItemRecommended Action
2Salt formsCall
DailyMed_get_spl_sections_by_setid
(chemistry section)
3Mutant ESR1 bindingFilter ChEMBL activities for ESR1 Y537S, D538G variants
5Phase count breakdownCompute counts from
search_clinical_trials
results
7PharmGKB guidelinesPharmGKB API unavailable; used label PGx instead [✓]
章节缺失项建议操作
2盐型调用
DailyMed_get_spl_sections_by_setid
(化学章节)
3突变ESR1结合筛选ChEMBL活性数据中的ESR1 Y537S、D538G变异体
5试验阶段计数细分
search_clinical_trials
结果中计算计数
7PharmGKB指南PharmGKB API不可用;已使用标签药物基因组学数据替代 [✓]

Tool Failures Encountered

遇到的工具失效

ToolErrorFallback Used
PharmGKB_search_drugs
API timeoutDailyMed label PGx sections [✓]
ADMETAI_predict_toxicity
Invalid SMILESFDA label warnings section [✓]
工具错误使用的备用方案
PharmGKB_search_drugs
API超时DailyMed标签药物基因组学章节 [✓]
ADMETAI_predict_toxicity
SMILES无效FDA标签警告章节 [✓]

Data Confidence Assessment

数据置信度评估

SectionConfidenceEvidence TierNotes
1. IdentityHigh★★★PubChem + ChEMBL confirmed
2. ChemistryMedium★★☆Missing salt form details
3. MechanismHigh★★★FDA label + ChEMBL bioactivity
4. ADMETMedium★★☆Predictions only; no clinical PK
5. ClinicalHigh★★★156 Phase 3 trials analyzed
6. SafetyHigh★★★FAERS + label warnings
7. PGxLow★☆☆PharmGKB unavailable; label only
章节置信度证据等级说明
1. 身份★★★PubChem + ChEMBL确认
2. 化学★★☆缺失盐型细节
3. 作用机制★★★FDA标签 + ChEMBL生物活性
4. ADMET★★☆仅预测数据;无临床药代动力学
5. 临床★★★分析了156项3期试验
6. 安全性★★★FAERS + 标签警告
7. 药物基因组学★☆☆PharmGKB不可用;仅标签数据

Quality Control Metrics (Section 11.3)

质量控制指标(第11.3节)

Data Recency

数据时效性

SourceLast UpdatedData AgeStatus
PubChem2026-02-01< 1 week✓ Current
ChEMBL v332025-12-152 months✓ Current
FAERS2026-01-01 (2026Q1)< 1 month✓ Current
DailyMed2025-11-20 (label revised)3 months✓ Current
PharmGKBN/A (unavailable)-⚠ Missing
Recency Assessment: All data sources current (< 6 months). PharmGKB unavailable; fallback used.
来源最后更新日期数据时长状态
PubChem2026-02-01<1周✓ 最新
ChEMBL v332025-12-152个月✓ 最新
FAERS2026-01-01 (2026Q1)<1个月✓ 最新
DailyMed2025-11-20(标签修订)3个月✓ 最新
PharmGKBN/A(不可用)-⚠ 缺失
时效性评估: 所有数据来源均为最新(<6个月)。PharmGKB不可用;已使用备用方案。

Cross-Source Validation

跨来源验证

PropertyPubChemChEMBLDailyMedAgreement
Molecular Weight378.88378.88378.88✓ Exact match
Half-lifeN/AN/A27 hoursSingle source
Primary targetN/AESR1ESR1✓ Confirmed
BioavailabilityPredicted: 85%N/A~60% (fed)⚠ Discrepancy
Contradictions Detected:
  • Bioavailability: ADMET-AI predicts 85%, but label reports ~60% (fed state). Resolution: Use label value (T1: ★★★) over prediction (T2: ★★☆).
特性PubChemChEMBLDailyMed一致性
分子量378.88378.88378.88✓ 完全匹配
半衰期N/AN/A27小时单一来源
主要靶点N/AESR1ESR1✓ 确认一致
生物利用度预测: 85%N/A~60%(进食状态)⚠ 差异
检测到矛盾:
  • 生物利用度: ADMET-AI预测85%,但标签报告~60%(进食状态)。解决: 使用标签值(T1: ★★★)而非预测值(T2: ★★☆)。

Completeness Score

完整性评分

Overall: 85% (17/20 minimum requirements met)
CategoryScoreDetails
Identity & Structure100%5/5 - All identifiers present
Chemistry80%4/5 - Missing salt form
Mechanism90%9/10 - Minor gap in off-targets
Clinical Development95%19/20 - Comprehensive trial data
Safety100%10/10 - FAERS + label complete
Pharmacogenomics60%3/5 - PharmGKB unavailable
Regulatory80%4/5 - US only, no EMA/PMDA
总体: 85%(20项最低要求中满足17项)
类别评分细节
身份与结构100%5/5 - 所有标识符均存在
化学80%4/5 - 缺失盐型
作用机制90%9/10 - 脱靶效应存在微小空白
临床开发95%19/20 - 全面的试验数据
安全性100%10/10 - FAERS + 标签完整
药物基因组学60%3/5 - PharmGKB不可用
监管80%4/5 - 仅美国数据,无EMA/PMDA

Evidence Distribution

证据分布

TierCountPercentageInterpretation
T1 (★★★)4565%High-quality regulatory/experimental
T2 (★★☆)1826%Computational predictions, PharmGKB
T3 (★☆☆)57%Literature inference
T4 (☆☆☆)11%Speculation
Quality Assessment: 91% of claims backed by T1/T2 evidence. Report meets publication standards.
Recommendation: Address missing items in Sections 2, 3, 5 for publication-quality report.

---
等级计数百分比解读
T1 (★★★)4565%高质量监管/实验数据
T2 (★★☆)1826%计算预测、PharmGKB数据
T3 (★☆☆)57%文献推断
T4 (☆☆☆)11%推测
质量评估: 91%的结论由T1/T2证据支持。报告符合发表标准。
建议: 补充第2、3、5节的缺失项,以达到发表级报告标准。

---

Fallback Chains

备用链

Primary ToolFallbackUse When
PubChem_get_CID_by_compound_name
ChEMBL_search_compounds
Name not in PubChem
ChEMBL_get_molecule_targets
Use
ChEMBL_search_activities
instead
Avoid this tool (returns irrelevant targets)
ChEMBL_get_bioactivity_by_chemblid
PubChem_get_bioactivity_summary_by_CID
No ChEMBL ID
DailyMed_search_spls
PubChem_get_drug_label_info_by_CID
DailyMed timeout
PharmGKB_get_dosing_guidelines
DailyMed_get_spl_sections_by_setid
(pharmacogenomics)
PharmGKB API error
PharmGKB_search_drugs
DailyMed_get_spl_sections_by_setid
+
PubMed_search_articles
PharmGKB unavailable
FAERS_count_reactions_by_drug_event
Document "FAERS unavailable" + use label AEsAPI error
ADMETAI_*
(all tools)
DailyMed_get_spl_sections_by_setid
(clinical_pharmacology, pharmacokinetics)
Invalid SMILES or API error

主工具备用工具使用场景
PubChem_get_CID_by_compound_name
ChEMBL_search_compounds
名称未收录于PubChem
ChEMBL_get_molecule_targets
改用
ChEMBL_search_activities
避免使用此工具(返回无关靶点)
ChEMBL_get_bioactivity_by_chemblid
PubChem_get_bioactivity_summary_by_CID
无ChEMBL ID
DailyMed_search_spls
PubChem_get_drug_label_info_by_CID
DailyMed超时
PharmGKB_get_dosing_guidelines
DailyMed_get_spl_sections_by_setid
(pharmacogenomics)
PharmGKB API错误
PharmGKB_search_drugs
DailyMed_get_spl_sections_by_setid
+
PubMed_search_articles
PharmGKB不可用
FAERS_count_reactions_by_drug_event
记录“FAERS不可用” + 使用标签不良反应API错误
ADMETAI_*
(所有工具)
DailyMed_get_spl_sections_by_setid
(clinical_pharmacology, pharmacokinetics)
SMILES无效或API错误

Quick Reference: Tools by Use Case

快速参考: 按用例划分的工具

Use CasePrimary ToolFallbackEvidence
Name → CID
PubChem_get_CID_by_compound_name
ChEMBL_search_compounds
★★★
SMILES → CID
PubChem_get_CID_by_SMILES
-★★★
Properties
PubChem_get_compound_properties_by_CID
ADMETAI_predict_physicochemical_properties
★★★ / ★★☆
Salt forms
DailyMed_get_spl_sections_by_setid
(chemistry)
-★★★
Formulation
DailyMed_get_spl_sections_by_setid
(description, inactive_ingredients)
-★★★
Drug-likeness
ADMETAI_predict_physicochemical_properties
Calculate from properties★★☆
FDA MOA
DailyMed_get_spl_sections_by_setid
(mechanism_of_action)
-★★★
Targets
ChEMBL_search_activities
ChEMBL_get_target
DGIdb_get_drug_info
★★★
Avoid
ChEMBL_get_molecule_targets
Use activities-based approachN/A
Bioactivity
ChEMBL_search_activities
PubChem_get_bioactivity_summary_by_CID
★★★
Absorption
ADMETAI_predict_bioavailability
DailyMed
clinical_pharmacology
★★☆ / ★★★
BBB
ADMETAI_predict_BBB_penetrance
DailyMed
clinical_pharmacology
★★☆ / ★★★
CYP
ADMETAI_predict_CYP_interactions
DailyMed
drug_interactions
★★☆ / ★★★
Toxicity
ADMETAI_predict_toxicity
DailyMed
warnings_and_cautions
★★☆ / ★★★
Trials
search_clinical_trials
-★★★
Phase countsCompute from
search_clinical_trials
results
-★★★
Trial outcomes
extract_clinical_trial_outcomes
-★★★
FAERS
FAERS_count_reactions_by_drug_event
Label adverse_reactions★★★
Dose mods
DailyMed_get_spl_sections_by_setid
(dosage_and_administration, warnings)
-★★★
Label
DailyMed_search_spls
PubChem_get_drug_label_info_by_CID
★★★
PGx
PharmGKB_search_drugs
DailyMed
pharmacogenomics + PubMed
★★☆ / ★★★
CPIC
PharmGKB_get_dosing_guidelines
DailyMed
pharmacogenomics
★★★ / ★★☆
Literature
PubMed_search_articles
EuropePMC_search_articles
Varies

用例主工具备用工具证据等级
名称 → CID
PubChem_get_CID_by_compound_name
ChEMBL_search_compounds
★★★
SMILES → CID
PubChem_get_CID_by_SMILES
-★★★
特性
PubChem_get_compound_properties_by_CID
ADMETAI_predict_physicochemical_properties
★★★ / ★★☆
盐型
DailyMed_get_spl_sections_by_setid
(chemistry)
-★★★
制剂
DailyMed_get_spl_sections_by_setid
(description, inactive_ingredients)
-★★★
类药性
ADMETAI_predict_physicochemical_properties
从特性计算★★☆
FDA作用机制
DailyMed_get_spl_sections_by_setid
(mechanism_of_action)
-★★★
靶点
ChEMBL_search_activities
ChEMBL_get_target
DGIdb_get_drug_info
★★★
避免使用
ChEMBL_get_molecule_targets
改用基于活性的方法N/A
生物活性
ChEMBL_search_activities
PubChem_get_bioactivity_summary_by_CID
★★★
吸收
ADMETAI_predict_bioavailability
DailyMed
clinical_pharmacology
★★☆ / ★★★
血脑屏障穿透
ADMETAI_predict_BBB_penetrance
DailyMed
clinical_pharmacology
★★☆ / ★★★
CYP相互作用
ADMETAI_predict_CYP_interactions
DailyMed
drug_interactions
★★☆ / ★★★
毒性
ADMETAI_predict_toxicity
DailyMed
warnings_and_cautions
★★☆ / ★★★
临床试验
search_clinical_trials
-★★★
试验阶段计数
search_clinical_trials
结果中计算
-★★★
试验结局
extract_clinical_trial_outcomes
-★★★
FAERS
FAERS_count_reactions_by_drug_event
标签adverse_reactions★★★
剂量调整
DailyMed_get_spl_sections_by_setid
(dosage_and_administration, warnings)
-★★★
标签
DailyMed_search_spls
PubChem_get_drug_label_info_by_CID
★★★
药物基因组学
PharmGKB_search_drugs
DailyMed
pharmacogenomics + PubMed
★★☆ / ★★★
CPIC指南
PharmGKB_get_dosing_guidelines
DailyMed
pharmacogenomics
★★★ / ★★☆
文献
PubMed_search_articles
EuropePMC_search_articles
可变

Common Use Cases

常见用例

Approved Drug Profile

获批药物概况

User: "Tell me about metformin" → Full 11-section report emphasizing clinical data, FAERS, PGx
用户: "介绍一下二甲双胍" → 完整11节报告,重点关注临床数据、FAERS、药物基因组学

Investigational Compound

研究中化合物

User: "What do we know about compound X (ChEMBL123456)?" → Emphasize preclinical data, mechanism, early trials; safety sections may be sparse
用户: "我们对化合物X (ChEMBL123456)了解多少?" → 重点关注临床前数据、作用机制、早期试验;安全性章节可能内容较少

Safety Review

安全性审查

User: "What are the safety concerns with drug Y?" → Deep dive on FAERS, black box warnings, interactions, PGx; lighter on chemistry
用户: "药物Y的安全性问题有哪些?" → 深入分析FAERS、黑框警告、相互作用、药物基因组学;简化化学部分

ADMET Assessment

ADMET评估

User: "Evaluate this compound's drug-likeness [SMILES]" → Focus on Sections 2 and 4; other sections may be brief or N/A
用户: "评估此化合物的类药性 [SMILES]" → 重点关注第2、4节;其他章节可简略或标注N/A

Clinical Development Landscape

临床开发现状

User: "What trials are ongoing for drug Z?" → Heavy emphasis on Section 5; trial tables with status, phases, indications

用户: "药物Z有哪些正在进行的试验?" → 重点关注第5节;试验表格包含状态、阶段、适应症

When NOT to Use This Skill

何时不使用此技能

  • Target research → Use target-intelligence-gatherer skill
  • Disease research → Use disease-research skill
  • Literature-only → Use literature-deep-research skill
  • Single property lookup → Call tool directly
  • Structure similarity search → Use
    PubChem_search_compounds_by_similarity
    directly
Use this skill for comprehensive, multi-dimensional drug profiling.

  • 靶点研究 → 使用target-intelligence-gatherer技能
  • 疾病研究 → 使用disease-research技能
  • 仅文献研究 → 使用literature-deep-research技能
  • 单一特性查询 → 直接调用工具
  • 结构相似性搜索 → 直接使用
    PubChem_search_compounds_by_similarity
此技能适用于全面、多维度的药物分析。

Key Improvements Summary

关键改进摘要

Based on real-world testing (elacestrant case study), these workflow improvements address common gaps:
基于真实世界测试(elacestrant案例研究),以下工作流改进解决了常见空白:

1. Chemistry Completeness

1. 化学完整性

  • ✅ Add salt/polymorph information from DailyMed chemistry section
  • ✅ Include pKa and experimental solubility
  • ✅ Embed 2D structure image (PubChem link)
  • ✅ Document formulation details and excipients
  • ✅ 从DailyMed化学章节添加盐型/多晶型信息
  • ✅ 包含pKa和实验溶解度
  • ✅ 嵌入2D结构图片(PubChem链接)
  • ✅ 记录制剂细节和辅料

2. Mechanism Depth

2. 作用机制深度

  • ✅ Quote FDA label MOA text verbatim (authoritative source)
  • ✅ Add target selectivity table (including mutant forms for relevant drugs)
  • ✅ Derive targets from ChEMBL activities (avoid
    ChEMBL_get_molecule_targets
    )
  • ✅ 逐字引用FDA标签作用机制文本(权威来源)
  • ✅ 添加靶点选择性表格(相关药物包含突变体)
  • ✅ 从ChEMBL活性数据推导靶点(避免使用
    ChEMBL_get_molecule_targets

3. Clinical Trial Accuracy

3. 临床试验准确性

  • ✅ Compute actual phase counts from search results
  • ✅ Separate by indication when relevant (e.g., breast cancer vs other)
  • ✅ Clearly label "representative trials" vs "all trials"
  • ✅ 从搜索结果中计算实际试验阶段计数
  • ✅ 必要时按适应症分开(例如:乳腺癌 vs 其他)
  • ✅ 明确标注“代表性试验” vs “所有试验”

4. Safety Completeness

4. 安全性完整性

  • ✅ Add FAERS seriousness breakdown
  • ✅ Document date window for FAERS data
  • ✅ Include FAERS limitations paragraph
  • ✅ Add dose modification triggers table (ALT/AST thresholds, renal/hepatic dosing)
  • ✅ 添加FAERS严重程度细分
  • ✅ 记录FAERS时间范围
  • ✅ 包含FAERS局限性段落
  • ✅ 添加剂量调整触发因素表格(ALT/AST阈值、肾/肝功能损伤给药方案)

5. Fallback Resilience

5. 备用链韧性

  • ✅ ADMET-AI failures → FDA label PK sections
  • ✅ PharmGKB failures → DailyMed PGx sections + PubMed
  • ✅ Type normalization for all IDs (prevent validation errors)
  • ✅ ADMET-AI失效 → FDA标签药代动力学章节
  • ✅ PharmGKB失效 → DailyMed药物基因组学章节 + PubMed
  • ✅ 所有ID的类型归一化(防止验证错误)

6. Quality Control

6. 质量控制

  • ✅ Automated completeness audit at report end
  • ✅ Missing data flagged with specific tool call recommendations
  • ✅ Tool failures documented with fallback status

  • ✅ 报告末尾的自动化完整性审核
  • ✅ 标记缺失数据并给出具体工具调用建议
  • ✅ 记录工具失效及备用方案状态

Additional Resources

附加资源

  • Tool reference: TOOLS_REFERENCE.md - Complete tool listing
  • Verification checklist: CHECKLIST.md - Pre-delivery verification
  • Examples: EXAMPLES.md - Detailed workflow examples
  • 工具参考: TOOLS_REFERENCE.md - 完整工具列表
  • 验证检查清单: CHECKLIST.md - 交付前验证
  • 示例: EXAMPLES.md - 详细工作流示例